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Chapter 1: INTRODUCTION  
1.1 Chronic Pain 
 The National Institute of Medicine estimates that over 116 million Americans 
have one or more chronic pain conditions that result in medical treatments and loss of 
productivity estimating $635 billion or more each year (IOM Report, 2011). The most 
effective treatment available for chronic pain management remains opioid 
pharmacotherapy (Gintzler and Chakrabarti, 2008). However, opioids often fail to 
achieve all the therapeutic goals for eliminating or significantly reducing the patient’s 
discomfort. It has been reported that only 20% of those using opioids for pain find them 
to be an effective, long lasting treatment (IOM Report, 2011). This is due in part to the 
fact that patients often have two or more causes or sources of their pain (Foley, 2000).  
There are also concerns with the patient and the prescriber for the possibility of opioid 
abuse and addiction.  Other limiting side effects include reduction in sensory thresholds 
and development of opioid tolerance following long term exposure. It is clear that 
alternative strategies for pain management are greatly needed.  This introduction will 
briefly review the current standard pharmacological treatments for chronic pain and 
opportunities for alternative approaches. This content establishes the foundation for the 
overall objective of the work featured in this thesis.  
 
1.2 Pharmacological Treatments for Chronic Pain 
 Great effort and collaboration has taken place between researchers, clinicians and 
organizations like the American Pain Society (APS) and the International Association for 
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the Study of Pain (IASP) to create clinical guidelines for non-malignant chronic pain. 
Currently, the guidelines recommend a, “multi-modal analgesic technique” when 
designing a chronic pain treatment regime for patients (Joshi, 2005). In 1986, the World 
Health Organization (WHO) developed a standard treatment protocol for practitioners to 
follow when treating pain termed the WHO Analgesic Ladder. These guidelines were 
initially established as a common framework for treatment of post-operative or cancer-
related pain. However, a similar strategy has been adopted when treating non-malignant 
chronic pain. Level 1 of the Analgesic Ladder describes appropriate treatment approaches 
for mild pain, which includes the use of non-opioid therapy such as acetaminophen, 
aspirin, and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDS). Adjuvant therapy 
may also be included at this level. If pain persists or intensifies, the treatment is taken to 
the second level for mild or moderate pain. Medications appropriate for this level include 
those traditionally considered milder opioids such as tramadol or codeine. At Level 2, 
adjuvants can be given in addition to opioids, but they must be non-opioid adjuvant 
therapies. Level 3 is intended to address severe pain with stronger opioids such as 
fentanyl, morphine, oxycodone, or methadone either alone or together with adjuvants. If 
at any point in this process toxicity or side effects emerge, the dosage is reduced and/or 
opioid rotation implemented.   
 The Analgesic Ladder has served as an effective unifying framework for pain 
management since 1986. As we progress in our understanding of pain mechanisms and 
pathology, advances in treatment technologies have called for revision of the ladder 
(Vargas-Schaffer, 2010). One modification includes building a fourth step of the 
  3 
Analgesic Ladder in order to incorporate more recently introduced interventional 
approaches when strong opioids become ineffective or to treat breakthrough pain crises. 
These strategies include, but may not be limited to implantation of epidural or intrathecal 
cathethers, transforaminal epidural steroid injections, neurosurgical interventions such as 
nerve blocks, or implantation of neurostimulation devices. It is likely that gene therapies, 
such as those proposed in this thesis, would fit on Level 4 of the Analgesic Ladder.  
 As the pharmacological, physiological, and sociological complexity of managing 
chronic pain, particularly with opioid medication, is increasingly recognized, the 
Analgesic Ladder may evolve such that alternative or more invasive therapies are not 
relegated to Level 4 but perhaps used in combination and as an adjuvant to Steps 1 and 2. 
The present thesis characterizes a gene therapeutic strategy that could be used in 
combination with opioid medication to 1) prevent the development of opioid-induced 
analgesic tolerance (and potentially addiction) and 2) to reduce dose requirements.  The 
next few sections, will provide a brief review of the opioid receptor analgesic system and 
the NMDA receptor system, which are the receptor targets for the proposed combined 
gene therapy + opioid pain management strategy.  
 
1.2.1 Opioids 
 As mentioned in the Introduction, the most effective treatment currently available 
for chronic pain sufferers remains opioid pharmacotherapy (Gintzler and Chakrabarti, 
2008). Yet, opioids often fail to achieve all the therapeutic goals for eliminating or 
significantly reducing the patient’s discomfort and are associated with many adverse 
  4 
side-effects. Opioids act in the central nervous system (CNS) at G protein-coupled 
receptors (GPCRs). Ninety-percent of GPCRs (excluding odorant and light receptors) are 
expressed in the CNS, with nearly 80% of the identified G protein coupled-receptor 
(GPCR) families play a role in pain modulation (Stone, 2009). Opioid receptors are G 
protein-coupled receptors that are located throughout the CNS with regionalization in 
areas relevant to the sensory pain pathway (e.g. spinal cord dorsal horn, rostral ventral 
lateral medulla, periaqueductal gray). This feature makes GPCRs ideal candidates for 
pharmaceutical applications involving chronic pain. A decades-old and intensive, 
ongoing investigation by academia and industry has attempted to optimize 
pharmacotherapy targeting inhibitory GPCRs (Gi) with limited success, especially in 
regards to chronic pain management  (Wess, 2007).  
 As this relates to pain signaling, the general mechanism of action for opioids is by 
activating both pre- and post-synaptic opioid receptors to inhibit pro-nociceptive 
signaling. The Gi protein has three subunits (αβγ )  that  dissociate from one another and 
then act on various distinct downstream pathways. Gα primarily works by inhibiting 
adenylyl cyclase, therefore reducing cAMP production, which in turn reduces activation 
of PKA. Gβγ subunits interact with the potassium ion channels in the post-synaptic 
neuron to increase intracellular potassium flow out of the cell resulting in 
hyperpolarization, which inhibits the neuron from carrying forward a signal, in this case, 
pain.  Gβγ subunits also act to block voltage gated calcium channels in the pre-synaptic 
neuron to reduce neurotransmitter release. Both of these actions result in prevention of 
the pain signal from being transmitted to the brain and interpreted as pain. Therefore, 
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when an opioid, such as morphine is given, these GPCR pathways are set in motion and 
analgesia ensues.     
 Yet, even after 40 years of opioid research, opioid therapy for pain often fails to 
achieve all the therapeutic goals for eliminating or significantly reducing the patient’s 
discomfort. This is mostly due to the fact that opioids are accompanied with a variety of 
adverse systemic side effects such as: sedation, dizziness, nausea, constipation, and risk 
of respiratory depression. Additionally, in the case of chronic use or chronic exposure to 
opioids, some individuals can experience opioid-induced hyperalgesia, where the opioid 
increases pain sensation.  
 Most relevant to the research presented here is the phenomenon of opioid-induced 
tolerance. Pharmacologically defined, tolerance is a statistically significant shift to the 
right in the dose-response curve. To a patient, this means their dose of opioid prescribed 
no longer results in adequate pain relief, resulting in an increase of the prescribed dose. 
The mechanisms involved in opioid tolerance have been described as a “moving target,” 
where the multiple points of cellular adaptions arise to compensate for chronic inhibition 
of excitatory input  (Gintzler and Chakraabarti, 2008).  
 
1.2.2 NMDA Receptor Antagonists as a Therapeutic Target for Preventing Opioid 
Analgesic Tolerance 
 The N-methyl-D-aspartate receptor (NMDA) is an ion channel expressed in the 
postsynaptic membrane that is important in the process of synaptic plasticity, which 
drives much of neuroadaptation.  The neurotransmitter glutamate is released from the 
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pre-synaptic neuron to communicate information, such as sensory stimulation (e.g. pain).  
Glutamate crosses the synapse and binds to, among other ion and G protein-coupled 
glutamate channels, the NMDA receptor. This results in calcium influx, which in turn 
results in the conversion of L-arginine to nitric oxide. Nitric oxide then diffuses 
retrogradely to the presynaptic neuron where it stimulates more release of glutamate. This 
process results in a fulminating feed-forward system, resulting in synaptic plasticity.  
 Pharmacological studies have shown that NMDA receptor antagonists (Bilsky et 
al., 1996; Elliott et al., 1994; Popik and Kozela, 1999; Trujillo and Akil, 1991) and nitric 
oxide synthase inhibitors (Babey et al., 1994; Elliott et al., 1995; Kolesnikov et al., 1992) 
prevent development of opioid-mediated tolerance (Drdla et al., 2009).  Intense industrial 
initiatives to develop clinically useful NMDA receptor antagonists have largely been 
hindered by limiting motor and cognitive side effects (Salter, 2005). However, these side 
effects are thought to be attributable to non-selective or high affinity NMDA receptor 
antagonists (Wood, 2005). Low affinity (memantine, amantadine) or NR2B subunit-
selective antagonists (ifenprodil) have recently been promoted as demonstrating a higher 
therapeutic index (Layton et al., 2006). These aforementioned adverse side effects are 
common limitations of traditional pharmacotherapeutic strategies; the proposed studies 
will circumvent these limitations by developing a gene therapeutic strategy augmenting 
an endogenous neurotransmitter thought to counter opioid tolerance. 
 The motor dysfunction of most NMDA receptor antagonists (i.e. MK801) can be 
detected on behavioral assays of motor dysfunction, such as rotarod. Interestingly, 
agmatine, a NMDA anatgonist, has no activity in the rotarod test (Fairbanks et. al., 2000). 
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It is noteworthy that such side effects are primarily observed with non-selective or high 
affinity NMDA receptor antagonists.  It has been suggested that the NR2B subunit-
selective antagonists have a lower side effect profile than traditional non-selective 
NMDA receptor antagonists due to site-restricted expression in the dorsal horn of the 
spinal cord (Mony, 2009). That restricted expression pattern predicts, and is consistent 
with, an expanded therapeutic window for NR2B selective antagonists (Suetake-Koga et 
al., 2006) relative to non-selective NMDA receptor antagonists. Based on observations 
that agmatine exhibits low toxicity, we have proposed that it may act selectively on the 
NR2B subunit of the NMDA receptor.  The experiments to test that proposal are an 
ongoing line of investigation in Dr. Fairbanks’s research program, but are not represented 
in this thesis research program. 
 
1.2.3 Decarboxylated Arginine (Agmatine): An NMDA Receptor Antagonist 
 Agmatine, the decarboxylated form of L-arginine, was discovered in the CNS in 
1994 and was subsequently shown to inhibit NMDA-evoked current (Yang and Reis, 
1999) and behavior (Roberts et al., 2005) as well as NO production (Galea et al., 1996). 
Later studies of exogenously delivered agmatine showed an inhibitory role in multiple 
models of neuroplasticity (Piletz et al., 2013).  Fairbanks and colleagues have 
demonstrated repeatedly that agmatine also prevents the development of opioid-induced 
tolerance (Fairbanks and Wilcox, 1997; Kitto and Fairbanks, 2006; Kolesnikov et al., 
1996; Morgan et al., 2002; Wade et al., 2008), similar to other NMDA receptor 
antagonists and NOS inhibitors, but without the common side effect of motor ataxia 
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(Fairbanks et al., 2000; Nguyen et al., 2003).  What separates agmatine from other 
NMDA receptor antagonists and NOS inhibitors is that it can be produced in vivo. The 
cloning of a synthetic (Morrissey et al., 1995) and degradative enzyme systems (Iyer et 
al., 2002) revealed a modulatable system that is also thought to be expressed in the CNS. 
Determining whether endogenously produced agmatine inhibits the development of 
opioid tolerance or chronic pain or other types of neural plasticity will provide important 
information as to the usefulness of targeting the agmatine metabolic pathway for 
therapeutic treatment.   
 
1.3 Gene Transfer Approaches for Treatment of Chronic Pain 
 Alternative approaches to pharmacotherapy are being developed through the field 
of gene therapy with the expectation to modify viruses to provide permanent therapeutic 
and beneficial treatments for a variety of CNS disorders. Viral vector gene transfer 
utilizes the innate ability of viruses to enter the cell and deliver genetic material for long-
term expression of biotherapeutic proteins.  As effective treatments for chronic pain are 
limited, there are a number of investigators exploring gene therapy for treatment of 
chronic pain, with the goal of providing long-lasting, constitutive pain relief with little to 
no side effects.  
 Chronic pain is defined as pain that persists (after healing has occurred) longer 
than 12 weeks. Chronic pain is widely believed to be a disease, with known changes in 
the nerves that deteriorate with time (IOM, 2011). As the mechanisms underlying the 
development and persistence of chronic pain become better understood, new 
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opportunities for genetic interventions may emerge. To date, there have been several 
primary gene therapy approaches explored for treatment of pre-clinical models of chronic 
pain. Two primary approaches will be reviewed in the in the next few sections.  
 
1.3.1 Herpes Simplex Virus: Endogenous Opioids 
 It is known that viruses can be modified in such a way as to provide therapeutic or 
beneficial treatments in gene therapy. The use of the herpes simplex virus (HSV) to 
deliver genes is one common example of this technique. Most studies have shown 
benefits of gene therapy in animal models and recently Phase I human clinical trials using 
HSV vectors for irretractable cancer pain (Kumar, Ruchi, James, and Chidiac, 2011). 
Specific to pain relief, previous gene therapy studies have utilized HSV to carrying 
coding for endogenous opioids such as beta-endorphin (Wolfe, 2007) or pre-
proenkephalin (Glorioso, 2003; Yoshimura 2001; Westlund, 2009; Westlund and Vera-
Portocarrero, 2012; Yang et al., 2008). Because HSV has a natural affinity to transfect 
neuronal cells and establish a latent infection in the dorsal root ganglion sensory neurons 
of the host, the HSV is an effective and convenient method for the delivery of gene 
therapy.  The HSV vector can also cross the blood brain barrier and will persist in 
neurons and have been shown to be effective as brain tumor treatments (Latchman, 2001) 
and other various neurological disorders (Hester, Foust, Kaspar, and Kaspar, 2009). 
 The HSV gene sequences that cause an active infection are modified so that lytic 
infection does not manifest. Yet, a major concern lies in the fact that HSV vectors at 
higher titers have the possibility of reverting back to a wild-type phenotype (Fialho, 
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2010; Jamieson, 1995) and therefore could potentially reactivate a latent HSV infection; 
thereby risking HSV induced encephalitis or death. Interruption to the transcriptional 
silence may be induced by external factors such as stress, trauma or exposure to certain 
drugs, resulting in a reactivation of the lytic cycle (Blondeau, Aoki, and Glavin, 1993). 
This means the HSV gene therapies are often developed with a reduced concentration or 
period of transgene expression, which may limit HSV vectors for the use in chronic pain 
conditions (Gillet, Macadangdang, Fathke, Gottesman, and Kimchi-Sarfaty, 2009). 
 
1.3.2 Adeno-Associated Viral Vectors 
 The adeno-associated virus (AAV) has risen to the forefront of gene therapy 
(Beutler and Reinhardt, 2009). This is in large part due to lack of pathogenicity and its 
variety of serotypes that enable specific cell-targeted entry (Gao, Vandenberghe and 
Wilson, 2005). The AAV is also nonpathogenic and is naturally replication defective. 
Several cell surface receptors have been identified that allow for AAV to be categorized 
into different serotypes (Mason et al., 2010). To date, twelve functional serotypes have 
been discovered and continue to be characterized (Miyake et al., 2012). Most research 
has focused on AAV serotypes 1 through 9, which have considerable differences at the 
capsid amino-acid sequence level (Daya and Berns, 2008). Because the viral capsid is the 
primary interface between the host and vector genome, it is believed that the capsid 
moderates specificity of transduction.   
  A study by Zincarelli et al., determined the tissue tropism of nine AAV serotypes 
(all vectors similarly prepared) via one route of delivery (2008). The results yielded three 
  11 
categories of expression and two classes of kinetics  (Zincarelli, Soltys, Rengo, and 
Rabinowitz, 2008). The unique characteristics and tissue specificity of each AAV 
serotype has made AAV gene therapy a hopeful leader in the translation of animal-based 
research to human clinical trials (Beutler and Reinhardt, 2009) and is one of the reasons 
why AAV is currently the fastest growing viral vector used for gene transfer research and 
clinical trials (Daya and Berns, 2008). Just in the past five years the use of AAV vectors 
in world wide clinical trials, has risen from 4.4% to 5.5% (Wiley, 2014).  
 
1.3.3 Viral Vector Gene Transfer with Arginine Decarboxylase (ADC) 
 As stated earlier, attempts to manage opioid tolerance for those requiring chronic 
opioid analgesic therapy using NMDA receptor antagonists/NOS inhibitors have been 
significant but with limited effectiveness. The escalating reluctance to use opioid 
medications brings a challenge of identifying new approaches to provide effective pain 
management.  
 Previous gene therapy approaches have, for the most part, attempted 
overexpression of opioid neuropeptides. There has not yet been an emphasis on 
developing gene therapy as a complement to the use of opioid medications. Such an 
approach could prevent the dose-escalation that arises with chronic opioid.  Previous 
findings would suggest that agmatine may be a good candidate for such a therapy. Since 
agmatine is produced endogenously, the opportunity arises to develop a method for 
enhancing expression of arginine decarboxylase (ADC) to create agmatine locally and 
constitutively via gene therapy.  
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 Region-directed genetic modulation of the agmatine metabolic pathway at the 
spinal level could be a highly innovative approach for control of opioid tolerance or 
chronic pain without interfering with ongoing neuroplasticity required for normal brain 
functions, such as learning and memory. If this approach is established with proof-of-
concept studies, other opportunities to regionally modify the agmatine system will likely 
emerge. The ability to alter negative neuroadaptation (such as opioid analgesic tolerance) 
without interfering with appropriate neuroadaptation (such as learning and memory) 
could significantly improve the therapeutic options of using opioids for treatment of 
chronic pain. 
 
1.4 Thesis Objectives  
 It is my central hypothesis that increasing the amount of the synthetic enzyme of 
arginine decarboxylase (ADC) expressed in the CNS will increase levels of agmatine and 
prevent the development of opioid analgesic tolerance in a site-specific manner. Through 
this thesis work, we sought to determine whether intrathecal delivery of adeno-associated 
virus serotype 5 - human arginine decarboxylase (AAV5-hADC) would result in gene 
transfer of hADC to CNS sites, relevant to sensory system and opioid receptor signaling. 
I also sought to determine if subjects (mice) treated with AAV5-hADC would be able to 
prevent the development of analgesic tolerance to either morphine or the opioid 
neuropeptide endomorphin-2. Such a result would be analogous to what is observed with 
intrathecal delivery of agmatine. I also sought to determine whether spinal cords 
extracted from AAV5-hADC-treated subjects (mice) have a higher concentration of 
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agmatine, which would support the proposal that increased expression of arginine 
decarboxylase results in the production of elevated agmatine in the CNS. Finally, 
following the observation that intrathecal injection of AAV5-hADC results in gene 
transfer to the choroid plexus of the fourth ventricle, I also sought to further evaluate the 
suitability of the choroid plexus cells as a target tissue for therapeutic gene transfer.  
 
1.4.1 Thesis Preview 
 
 In this thesis, I first report the following: The effects of AAV5-hADC gene 
transfer in two models of opioid-induced tolerance. Second, I present the quantification 
of agmatine and putrescine in tissues of animals treated with AAV5-hADC. Lastly, I 
describe the in vitro expression pattern of AAV-GFP treated choroid plexus cultures, in 
both primary and immortalized cell cultures.  The data presented in this thesis provides 
proof-of-concept that intrathecal delivery of AAV5-hADC viral vector results in region 
specific expression of human arginine decarboxylase, and elevated concentration of 
agmatine in spinal cord relative to control.  Additionally, I determined that the intrathecal 
delivery of AAV5-hADC results in gene transfer of hADC to the choroid plexus of the 
4th ventricle, suggesting an additional, previously unconsidered target for gene transfer 
for therapeutic treatment of pain. The chapters are summarized below. 
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1.4.2 Chapter 2 
 In Chapter 2, the expression and distribution of hADC following AAV5-hADC 
intrathecal delivery in mice is presented together with the functional effects of AAV5-
hADC expression on analgesic tolerance induced by chronic systemic delivery of 
morphine and acute intrathecal delivery of high dose endormophin-2. Additionally, a 
study of immunoneutralization of presumed elevated endogenous agmatine indirectly 
supports the proposal that the overexpressed hADC produces spinal agmatine.  
 
1.4.3 Chapter 3 
  In Chapter 3, the challenges associated with bioanalytical detection of agmatine 
in CNS tissue are reviewed. Application of the recently introduced technology of heat 
stabilization is described as well as additional modifications to a previously established 
HPLC technique to improve detection of agmatine as well as separation from its primary 
metabolite, putrescine.  Finally, analysis of heat-stabilized spinal cord extracted from 
AAV5-hADC-treated mice compared to saline-controls for agmatine content is presented.  
The data support the proposal that AAV5-hADC treatment results in elevated agmatine 
levels in spinal cord.  
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1.4.4 Chapter 4 
 The choroid plexus may be an advantageous target for the delivery of AAV gene 
therapy for neurological disorders. Delivering AAV gene transfer via intrathecal injection 
utilizes the CSF in the subarachnoid space to reach the apical side (CSF side) of the 
choroid plexus. In Chapter 4, gene transfer to primary choroid plexus cultures, Z310 cells 
(an immortalized choroid plexus cell line), as well as choroid plexus explants were used 
to characterize the expression pattern and time course of diverse AAV serotypes to 
transduce epithelial cells of the murine choroid plexus.  
1.4.5 Summary  
 
 Through implementation of my thesis research I have accomplished several 
objectives.  First, I evaluated the functional impact of spinal expression of the synthetic 
gene of agmatine: I found that overexpression of ADC resulted in a similar 
pharmacological profile as that observed when agmatine is given intrathecally (Fairbanks 
and Wilcox, 1997; Wade et al., 2009). Second, I identified a new approach to improve the 
detection of agmatine in CNS tissue, enabling the observation that AAV-hADC treatment 
elevates agmatine in spinal cord. Third, I have established a new line of investigation to 
characterize gene transfer to choroid plexus for consideration of the usefulness of 
targeting that tissue for chronic pain management.  
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CHAPTER 2: Adeno-associated virus mediated gene transfer of arginine 
decarboxylase to the central nervous system reduces morphine analgesic tolerance.  
 
CHAPTER SYNOPSIS  
 The decarboxylated form of L-arginine, agmatine, has been shown to prevent the 
development of opioid analgesic tolerance, dependence, and self-administration when 
given by both systemic and central routes of delivery.  Agmatine has been reported to be 
located in brain and spinal cord, as has the expression of its synthetic enzyme, arginine 
decarboxylase (ADC). The presence of a biochemical synthesis pathway for agmatine 
offers the opportunity for overproduction of agmatine for local therapeutic delivery to 
regions where opioid analgesic tolerance is thought to arise. The effects of adeno-
associated virus (AAV) gene transfer of human ADC (hADC) in two models of opioid-
induced analgesic tolerance are reported here.  
 Eight weeks following initial intrathecal (i.t.) injections of vehicle- or AAV5-
hADC-treated, mice were treated with repeated subcutaneous (s.c.) injections of either 
saline or morphine (s.c.) for 3 days. On day 4 morphine (s.c.) challenge dose-response 
curves were constructed in all treatment groups.  In vehicle-treated subjects, a significant 
4-fold rightward shift in the morphine dose-response curve was observed in the morphine 
treatment group relative to saline control, as expected. However, in subjects pre-treated 
with AAV5-hADC, the morphine dose-response curves between saline-pretreated and 
morphine-pretreated groups were equivalent, indicating that morphine analgesic tolerance 
did not develop. Similarly, AAV5-hADC pre-treatment prevented the development of 
acute endomorphin-2 analgesic tolerance, an effect reversed by intrathecal injection of 
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anti-agmatine, but not normal, IgG. Post-experiment, mRNA analysis confirmed that 
AAV5-hADC-treated mice demonstrated presence of hADC mRNA in periaqueductal 
grey (PAG), fourth ventricle choroid plexus, cervical and lumbar spinal cord as well as 
corresponding dorsal root ganglia.   We conclude that the observed AAV5-hADC-
mediated prevention in morphine tolerance is associated with the expression of hADC in 
regions relevant to the sensory system.  
 
INTRODUCTION 
 A panel of complex side effects often accompanies long-term opioid 
pharmacotherapy, including, but not limited to, the development of opioid analgesic 
tolerance. The development of analgesic tolerance for patients on chronic opioid therapy 
can result in significant dose escalation (Chu et al., 2012; Duarte et al., 2012; Lorenz et 
al., 2002) which in turn result in an increase of adverse side effects (Chu et al., 2012), or 
a need for more invasive delivery approaches or the inability to adequately control pain 
(“ceiling effect”) (Lorenz et al., 2002).  Multiple strategies are used with varying success 
for such patients such as opioid rotation, drug holiday, or inclusion of adjuvant analgesics 
(Lorenz et al., 2002). It is recognized that the development of opioid analgesic tolerance 
is a highly adaptable event; such recognition emphasizes the challenge that has been the 
decades-long search to control the development of analgesic tolerance and suggests the 
value of a more targeted or site-specific strategy (Gintzler and Chakrabarti, 2008). 
 It has previously been shown that the decarboxylation product of L-arginine, 
agmatine, prevents the development of opioid analgesic tolerance when given either 
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systemically (Kolesnikov et al., 1996) or centrally (Fairbanks and Wilcox, 1997; Kitto 
and Fairbanks, 2006; Wade et al., 2009).  Evidence suggests that agmatine likely 
antagonizes the NMDA receptor (Roberts et al., 2005a; Wade et al., 2009; Yang and 
Reis, 1999) or inhibits the nitric oxide synthase enzyme (Auguet et al., 1995; Demady et 
al., 2001; Galea et al., 1996; Roberts et al., 2005a) to exert this anti-tolerance action. 
Twenty years of pharmacological studies have consistently shown that antagonism of the 
NMDA receptor (Bilsky et al., 1996; Elliott et al., 1994; Popik and Kozela, 1999; Trujillo 
and Akil, 1991) or inhibition of the nitric oxide synthase (NOS) enzyme (Babey et al., 
1994; Elliott et al., 1995; Kolesnikov et al., 1992) inhibits the development of opioid-
induced analgesic tolerance.  
 Since agmatine is synthesized by arginine decarboxylase, which is expressed in 
the central nervous system (CNS), an opportunity arises to develop an agmatine-based 
gene therapy with site-directed expression within the CNS. Toward this end, we have 
developed an adeno-associated viral vector that carries the gene for arginine 
decarboxylase to determine whether overexpression of agmatine in tissues relevant to 
pain and opioid neuropharmacology can reduce the development of opioid analgesic 
tolerance in mice.  An emerging body of literature suggests that such a gene therapy 
approach is likely to be clinically translatable with a long-term expression (Beutler and 
Reinhardt, 2009). 
 We have previously reported (Vulchanova et al., 2010) that through the delivery 
method of intrathecal injection via direct lumbar puncture and i.v. mannitol pretreatment, 
in conscious mice, we are able to achieve robust gene transfer to sensory neurons with 
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expression of a reporter gene in the dorsal root ganglia and at all levels of the spinal cord. 
We observed that in subjects injected with AAV5-GFP, but not pre-injected with i.v. 
mannitol, AAV5-GFP expression was not observed in spinal cord or brain parenchyma, 
but was detected in choroid plexus. Thus we hypothesized that selective delivery to the 
choroid plexus could be achieved via AAV5-mediated viral vectors.  
 Through using a similar, but modified approach, we are able to achieve AAV5-
mediated gene transfer of the human arginine decarboxylase (hADC) enzyme in lumbar 
and cervical spinal cord as well as supraspinal locations.  We hypothesized that 
overexpression of hADC along the sensory system would result in elevation of 
endogenous agmatine and reduce the development of opioid tolerance. To test this 
proposal, the development of chronic systemic morphine tolerance in AAV5-hADC-
treated mice and vehicle-injected controls was compared.  
 In this chapter, I describe our experimental design and biological evaluation of the 
impact of intrathecal delivery of AAV5-hADC-GFP, a vector that contains the synthetic 
gene for human arginine decarboxylase (hADC). The results of this study indicate that 
endogenously produced agmatine enhanced from overexpression of hADC in the dorsal 
root ganglia and spinal cord prevent the development of opioid tolerance. 
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MATERIALS & METHODS 
Animals 
 All experimental subjects were 20 to 25g adult male ICR-CD1 mice (Harlan, 
Madison, WI). All experiments were approved by the University of Minnesota 
Institutional Animal Care and Use Committee.  
 
Chemicals 
 Morphine sulfate was a gift from the National Institute on Drug Abuse. 
Endomorphin-2 (Endo-2) (YPFF) was synthesized by the University of Minnesota’s 
Microchemical Facility, Minneapolis, MN. 
 
 
 
AAV Vector and Packaging Gene Construct Development 
 The strategy for developing the AAV is described briefly here. Human ADC 
cDNA was cloned into the EcoRI and Xho1 sites of plasmid pAAV-IRES-hrGFP 
(Agilent Technologies) with assistance from the laboratory of Prof. R.S. McIvor 
(University of Minnesota). This viral construct also contained the gene for green 
fluorescence protein (GFP). The resulting plasmid pAAV-ADC contains the hADC 
expression cassette (CMV promoter-hADC cDNA-IRES-GFP and bovine growth 
hormone polyadenylation signal) flanked by AAV2 inverted terminal repeats (Figure 
2.1A). This vector was packaged into AAV5 virions at the University of Florida Vector 
Core by co-transfection of HEK293 cells and purified from cell lysates on an iodixanol 
step gradient followed by Q Sepharose ion exchange chromatography (Zolotukhin et al., 
2002). The vector titer was 8.24 x 1012 vector genomes/mL (vg/ml) for AAV5-hADC-
GFP. 
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Gene Expression by RT-PCR   
 Total RNA was extracted from tissue or cell lines using RNAzol RT (Molecular 
Research Center, Cincinnati, OH) according to manufacturer’s suggestions.  
Approximately 1.3 micrograms of this RNA was reverse transcribed.  Briefly, the RNA 
was added to a reverse transcription (RT) master mix (final concentrations: 2.5 U 
Multiscribe murine leukemia virus reverse transcriptase, 2.5 mM random hexamers, 200 
µM of each dNTP, 5 U RNase inhibitor, 5.0 mM dithiothreitol, 1.75 mM MgCl2, 30 mM 
tris-HCl and 20 mM KCl; pH 8.3) in a volume of 40 µl.  cDNA synthesis was performed 
in a thermal cycler (BioRad Mini) with the following program: 25°C for 5 minutes 
(primer annealing), 42°C for one hour (primer extension) and 65°C for 5 minutes 
(inactivation of the reverse transcriptase).  4.5 µl of RT reaction product was added to 10 
µl Lightcycler 480 SYBR green I Master (Roche, Indianapolis, IN) and 15 mM of each 
forward and reverse primer in a total of 20 ml per reaction.  The sequences of the primers 
used are shown in Table 1.  PCR amplification was performed in thermal cycler 
(Lightcycler 480 II, Roche) using the following program: 1 cycle of 95˚C for 5 minutes 
(DNA polymerase activation) followed by 50 cycles of 95˚C for 10 seconds (DNA 
denaturation), 57˚C for 10 seconds (primer annealing) and 72˚C for 10 seconds (primer 
extension). PCR amplification was followed by built-in melting temperature and cooling 
programs.  Ten µl of PCR product was fractionated through a 1.5% agarose gel, 
visualized by ethidium bromide staining and imaged using a digital workstation 
(BioRad). 
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Antinociceptive Testing 
 Nociceptive responsiveness was tested using the warm water (52.5°C) immersion 
tail-flick assay (Janssen et al., 1963). Baseline measurements of tail-flick latencies were 
collected on all subjects (for a sample of n = 42 , mean = 3.32 s, and S.D. = 0.65 s). Each 
animal’s baseline was used as its own control. The percent maximum possible effect 
(%MPE) was calculated accordingly: %MPE = (postdrug latency – predrug 
latency)/(cutoff – predrug latency) x 100%. To avoid tissue injury, a maximum score of 
100% was assigned to those animals not responding before the 12 second cutoff.  
 
Statistics 
  In Table 3, the ED50 values and 95% confidence intervals (CIs) of drugs were 
calculated by parametric linear regression analysis of the log dose–response curves. A 
minimum of three to four doses was used to construct the dose–response curve for each 
pre-treatment group. When evaluating the significance of a potency shift between the 
experimental pre-treatment groups and the saline control group, a relative potency ratio 
was calculated and t-test (p<0.05) performed. These methods have been previously 
described by Tallarida and Murray (1987). These calculations were performed using the 
pharmacological statistics software FlashCalc (Dr. Michael Ossipov, University of 
Arizona, Tucson, AZ) 
Injections 
 The AAV5-hADC construct was delivered intrathecally (i.t.) by direct lumbar 
puncture in awake mice (Hylden and Wilcox, 1980) by an experimenter (KFK) with over 
20 years experience in this method of drug delivery. A minor modification of the protocol 
  27 
was required to conserve the AAV5-hADC vector. The needle (30-gauge, 0.5-inch) was 
connected to a length of PE10 tubing, which was then connected to a second needle (a 
30-gauge, 0.5-inch) that was attached to a 50-µl Luer-hub Hamilton syringe. For both 
AAV5-hADC experiments, 10 µL of the construct containing 8.24 x1012 viral vector 
genomes were injected intrathecally. The injection was administered by gripping gently 
the iliac crest of the rodent and inserting the needle (bevel side up) at about a 45° angle 
centered on the ileac crest. A reflexive flick of the tail indicated puncture of the dura. 
Following the injection, the animals were returned to the vivarium where they remained 
until the day of rotarod assay, tolerance injections, and tail-flick assay. This was eight-
weeks for the chronic morphine experiments and nine-weeks for acute morphine. 
Extraction of spinal cord, fourth ventricle choroid plexus, midbrain (PAG), liver and 
DRG for RT-PCR took place on the last day of behavioral testing, after all behavioral 
testing had been completed.   
 
Chronic Opioid Analgesic Tolerance Induction: Morphine 
  Mice were made tolerant to the analgesic effect of morphine by repeated 
administration of subcutaneous morphine over the course of three days. A single injection 
of was delivered on day 1 (3 mg/kg). Three injections were delivered at 9 am, 5 pm, and 
11 pm on Days 2 (3 mg/kg) and 3 (5 mg/kg). A total of seven subcutaneous injections 
were received over the course of the induction schedule.  A control group of mice 
received an equivalent number of subcutaneous saline injections concurrently with the 
morphine-treatment group. All injections were delivered in a volume of 100 
microliters/10 grams.   
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Acute Opioid Analgesic Tolerance Induction: Endomorphin-2 
 Mice were made tolerant to the analgesic effect of endomorphin-2 (Endo-2) by a 
single intrathecal injection of a large dose (10 nmol) of Endo-2.  Baseline tail flick 
latencies were collected on all mice (52.5°C). Saline or Endo-2 was injected. Thirty 
minutes later, tail flick latencies were taken again and the latencies had returned to 
baseline levels. Cumulative dose-response curves were constructed in the following way. 
A single dose of Endo-2 was injected, and the tail flick latency was taken at 2.5 minutes 
later (the peak analgesic time point). Thirty-minutes later, a second cumulative dose of 
Endo-2 was delivered and the process repeated. Doses were delivered in this fashion until 
a complete dose-response curve was constructed.  
 
Immunoneutralization Experiments: Opioid Analgesic AcuteEndomorphin-2 Tolerance 
 These experiments were conducted with the same cohort of animals used for the 
acute Endo-2 tolerance experiments. However, five minutes prior to the induction of 
acute Endo-2 tolerance, either normal guinea pig IgG (150 ng) or anti-agmatine IgG (150 
ng) were injected intrathecally as a “pre-pre-treatment”. These products were raised in-
house and have been previously characterized by Wade and colleagues (2009).  
Cumulative Endo-2 dose-response curves were collected 30 minutes after the Endo-2 pre-
treatments as previously described.  
Rotarod Assay 
 After two training sessions, mice were given the opportunity to walk  for a 
maximum of 300 s on an accelerating (4–40 rpm) rotarod (Ugo Basile, Varese, Italy). We 
compared the latency to fall between the four treatment groups.   
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RESULTS  
Expression of Arginine Decarboxylase in the Sensory System 
 We hypothesized that overexpression of the synthetic enzyme for agmatine, 
arginine decarboxylase (ADC) in the sensory neurons of the dorsal root ganglia and 
spinal cord, would reduce opioid analgesic tolerance. By administering the vector 
described above (Figure 2.1A) we intended to confirm successful transduction of the viral 
vector in tissue, by green fluorescent protein (GFP) immunoreactivity. Unfortunately, in 
this case, the vector did not translate the GFP protein (Schuster, Schnell, and Fairbanks, 
data not shown).  Therefore an alternative method was used to confirm successful vector 
transduction via RT-PCR for presence of hADC mRNA.  
 Rodents express a form of ADC that is distinct from that of the human sequence, 
since a human form of ADC was inserted, we were able distinguish between the two 
ADC forms (mouse and human) in transduced tissue. Thus enabling the identification of 
the efficacy of gene transfer to the spinal cord and dorsal root ganglia. Our laboratory 
team members developed specific primers that could distinguish detection of human 
ADC (Table 1) from that of mouse ADC in order to be able to assess the outcome of gene 
transfer (Schnell, Fairbanks, et al., unpublished observation). In Figure 2.1B, it was 
shown that these specific primers can detect native human ADC present in human 
embryonic kidney (HEK) 293 cells, but do not detect mouse ADC in spinal cord tissue 
extracted from mice treated with AAV5-GFP, a standard control used in in vivo 
experiments.  These primers also fail to detect mouse ADC in mouse fibroblast 3T3 cells, 
but detect human ADC in 3T3 cells infected with AAV5-ADC-GFP vector. These 
experiments confirm the specificity of these primers for the human form of ADC.  
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 In two separate sets of subjects, 8.24 x 1010 vector genomes of AAV5-hADC-GFP 
were injected intrathecally by direct lumbar puncture into nerve-injured mice. The 
expression of hADC was evaluated along the neuraxis at lumbar and cervical levels both 
in spinal cord and DRG. In subjects treated with AAV5-hADC, mRNA for hADC was 
detected in at least one tissue in 94% of the subjects (Table 2). The hADC transcripts 
were not detected in any tissue in saline-treated subjects. RT-PCR analysis on anatomic 
components of sensory system-related tissues (e.g. lumbar and cervical spinal cord and 
DRG) revealed distribution along the neuraxis of the spinal cord and distally into portions 
of the brain (Figure 2.1C). This tissue distribution and the percentages of AAV5-hADC-
GFP expressed in these tissues are summarized in Table 2.   
 
AAV5-hADC Expression on Opioid Analgesic Tolerance 
 Having established that the AAV5-hADC construct transduced tissues relevant to 
the sensory pathway, as well as in regions that express the mu opioid receptor, our goal 
was to characterize the dose-response relationship of morphine in the condition of 
chronic systemic morphine tolerance in normal mice and in mice with elevated hADC 
expression. Therefore, dose-response curves were determined for the antinociceptive 
effects of morphine in the tail flick test in mice that had been intrathecally injected eight 
weeks prior with either AAV5-hADC or saline as a control to the gene therapy treatment.  
These two separate cohorts were then further divided into two groups; which received a 
series of seven subcutaneous saline or morphine injections over the course of three days. 
On day 4 all subject groups were subcutaneously injected sequentially with increasing 
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doses of acute challenge morphine (1, 3, 10 mg/kg.) mice. Acute challenge morphine 
dose-response curves were then constructed and compared between the saline and 
morphine-injected groups for each cohort (AAV5-hADC and saline eight week 
pretreatment groups). This general experimental design for this chronic morphine 
tolerance study in AAV5-hADC treated animals is illustrated in Figure 2.2.  
 The outcomes were then compared between the two cohorts. In the intrathecal 
saline pre-treatment group, repeated injections of s.c. morphine produced a 4-fold 
rightward shift in the morphine dose-response curve (Figure 2.3A) relative to the 
morphine dose-response curve in the group that received repeated s.c. saline (control 
group). Repeated morphine injections increased the acute morphine ED50 value (Table 
3). The significant rightward shift confirms the induction of systemic morphine tolerance 
in this model in the control condition. In contrast, when mice were pre-treated with 
intrathecal AAV5-hADC, repeated injections with morphine did not produce a significant 
shift in the acute challenge morphine dose-response curve compared to those repeatedly 
injected with s.c. saline (Figure 2.3B).  The ED50 values for morphine were equivalent 
between the two repeated injection groups (Table 2.3). The observation of no shift in the 
morphine dose-response curves indicates that morphine tolerance did not develop in 
subjects receiving the AAV5-hADC injection i.t..   
 
Anti-Agmatine IgG Reverses AAV5-hADC Inhibition of Opioid Analgesic Tolerance 
 To further determine whether the prevention of opioid tolerance in AAV5-hADC 
treated mice was attributable to an effect of the agmatine molecule, an alternative indirect 
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approach was used: Immunoneutralization. The impact of intrathecal delivery of an 
immunoneutralizing antibody (IgG-Ag) (Wade et al., 2009) was assessed in a model of 
opioid induced analgesic tolerance.  For this experiment, the opioid neuropeptide, 
endomorphin-2 (Endo-2) (YPFF) (Zadina et al., 1997) was used. It was previously 
demonstrated  (Stone 1997; Wade 2009) that higher intrathecal doses of Endo-2 (10-30 
nmol, it.) develop acutely induced analgesic tolerance. It was also shown previously, that 
intrathecal pre-treatment of an immunogammaglobulin (IgG) raised to selectively target 
agmatine (Fairbanks, 2000; Wade, 2009) sensitizes mice to the development of Endo-2 
analgesic tolerance induced by low doses (Wade 2009).  We elected to use this model of 
acute opioid tolerance to test for the effect of immunoneutralization of agmatine in the 
hADC-treated mice. See Figure 2.4 for the experimental design.  
 In this experiment, a cohort of age-matched mice served as controls to the AAV-
hADC treated mice. This control cohort was injected with either intrathecal saline or high 
dose of Endo-2 (10 nmol) to establish the magnitude of acute endomorphin-2 analgesic 
tolerance.  Thirty minutes after the initial high dose injection, mice were tested 
cumulatively with increasing doses of Endo-2.  The tail flick test was performed 2.5 
minutes after the test injection. In this experiment, control mice pre-treated with saline 
demonstrated analgesic potency with an ED50 value of 7.3 nmol.  Control mice pre-
treated with Endo-2 mice did not display analgesic efficacy and, therefore, acute 
tolerance was induced (Figure 2.5). In contrast AAV5-hADC-treated mice that were pre-
treated with Endo-2 demonstrated Endo-2 analgesia with a relative potency to saline of 
1.9 nmol, comparable to that of control mice pre-treated with saline (Figure 2.6).  These 
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same AAV5-hADC treated mice had received a pre-pre-treatment of normal GP-IgG 
(150 ng) as control to the AAV5-hADC treated mice that received a pre-pre treatment of 
anti-agmatine IgG (150 ng) prior to the high dose of Endo-2 used to induce acute 
tolerance.  The analgesic efficacy of Endo-2 in those mice (AAV5-hADC, Anti-Ag-IgG, 
Endo-2) was significantly ablated, comparable to those control mice that received a pre-
treatment of Endo-2 and in which acute tolerance to Endo-2 was demonstrated (Figure 
2.6).  This last experimental group shows that when the anti-agmatine IgG is given as a 
pre-pre-treatment to Endo-2 in the AAV5-hADC mice, that the protective effect of the 
AAV5-hADC treatment is reversed. We interpret this to mean that the elevated 
concentrations of agmatine are bound by the anti-agmatine IgG, rendering the elevated 
agmatine unavailable to exert its anti-opioid tolerance effect. This experiment supports 
the proposal that overexpression of AAV5-hADC results in production of agmatine that 
acts to prevent the development of spinal opioid analgesic tolerance induced by Endo-2 
and, perhaps, analogously morphine. 
 
Motor Impairment Assay 
In other experiments it has been observed that repeated intrathecal delivery of the 
primary metabolite of agmatine, putrescine, results in motor impairment (Peterson and 
Fairbanks, unpublished observations). Such an observation raises a concern about the 
constitutive production of agmatine from overexpression of hADC. To assess this 
potential toxicity, we evaluated the motor performance of all animals by the rotarod 
assay, a test frequently used to assess motor dysfunction. Prior to the morphine tolerance 
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experiments, all subjects were assessed for motor impairment by evaluating their 
performance in the accelerating rotarod assay for mice (Fairbanks et al., 2000). Following 
two training sessions, mice are allowed to walk for 300 s on a accelerating rotating rod. 
Normal mice can readily achieve this goal whereas mice with motor impairment are not 
able to complete the session.  No differences in rotarod performance were observed 
between treatment groups (Table 4).  These data indicate that the hADC-treated mice 
displayed no evidence of motor toxicity under the conditions of our experiments.  
Taken together, these data suggest that expression of human ADC in the central 
nervous system of mice treated with AAV5-hADC prevents the development opioid 
analgesic tolerance.  
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Figure 2.1: Intrathecal delivery of AAV5-ADC into adult mice results in widespread 
AAV5-ADC transduction associated with high-level expression of ADC throughout the 
spinal cord,  dorsal root ganglia and 4th ventricle choroid plexus. (A) Depiction of the 
therapeutic AAV construct. the human hADC cDNA regulated by a CMV promoter. This 
construct was packaged using AAV serotype 5 capsid or AAV serotype 9 capsid to 
produce AAV5-ADC or AAV9-ADC.  GFP was included in the construct separated from 
human ADC by an internal ribosome entry site (IRES) nucleotide sequence. (B) All PCR 
products were specific for each target. Human embryonic kidney cells (HEK293) were 
used as a positive control for hADC primers (lane 1, 273bp product); AAV5-GFP 
injected mouse spinal cord and wild type 3T3 cells were used as negative controls for 
hADC primers (lanes 2 and 3).  No hADC mRNA was detected in mouse tissue or 3T3 
fibroblast cell lines unless it had been infected with the AAV5-hADC construct; beta 
actin mRNA (250 bp product) was detected in all samples (lanes 5-8). (C)  After 
infection by intrathecal injection of the AAV5-hADC construct, hADC mRNA was 
detected near the site of injection (lumbar spinal cord and DRG) as well as further 
rostrally (cervical spinal cord and DRG) and in non-neuronal populations of the choroid 
plexus.  No PCR products were observed when either no RNA was used (no input 
mRNA) or no reverse transcriptase was included in the reverse transcription step (not 
shown) (Schnell and Fairbanks, unpublished observations). 
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Name of Primer Sequence 
hADC forward set 2 GCCTTGGACCTGTACTTCCC 
hADC reverse set 2 CTGGTCCGTGGATGGTTTCT 
b-actin forward qPCR TCATGTTTGAGACCTTCAACAC 
b-actin reverse qPCR ATGTCACGCACGATTTCCC 
 
Table 2.1: Primer sequences used in RT-PCR experiments (Schnell and Fairbanks, 
unpublished data). 
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Table 2.2: Percentage of AAV5-hADC-GFP Transduction. The hADC mRNA 
expression in various CNS tissue (DRG) at t=0 days following the initial 
intrathecal injection. Periaqueductal gray, choroid plexus, spinal cord (lumbar, 
cervical), and DRG (lumbar, cervical) tissues were microdissected from AAV5-
hADC injected mice. The tissues were assayed by RT-PCR for the presence of 
hADC mRNA as determined by agarose gel electrophoresis. 
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Figure 2.2: Study Timeline: Morphine Tolerance in animals treated with AAV5-hADC. 
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Figure 2.3: Effects on AAV5-hADC pre-treatment development of morphine tolerance. 
Analgesic dose-response curves to acute subcutaneous morphine challenge on Day 4 
following repeated subcutaneous  injections of either saline or morphine  (A) Control 
subjects. Repeated s.c. injections with morphine  (closed circles) decreased acute 
morphine potency and efficacy compared with subjects repeatedly injected with saline  
(open circles), indicating induction of chronic  morphine analgesic tolerance. (B) AAV5-
hADC treated subjects. Repeated s.c. injections with morphine  (closed triangles) 
demonstrated equivalent acute morphine potency and efficacy compared with subjects 
repeatedly injected with saline  (open triangles), indicating that induction of chronic  
morphine analgesic did not occur in this experimental group.  
 
 
  
A 
B 
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Table 2.3:  ED50 values and relative potency for all treatment groups. 
(* Significant difference relative to the saline pretreatment group) 
 
  
Group ED50 Value 
(mg/kg, s.c.) 
Relative Potency 
Compared to Saline 
Saline - Saline 7.2 (5.7 – 9.1) 1 
Saline - Morphine 27.8 (20.3 – 38.0)* 3.9 
AAV5-hADC – Saline 10.4 (7.8 –  13.9) 1.4 
AAV5-hADC - Morphine 11.9 (10.0 – 14.0) 1.65 
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Figure 2.4: Study Timeline: Acute endomorphin-2 Tolerance  in AAV5-hADC-treated animals. 
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Figure 2.5: Endomorphin-2 Acute Tolerance.  Analgesic dose-response curves to acute 
intrathecal endomorphin-2 challenge 30 minutes following an acute  injection of either 
saline or endomorphin-2. A high  dose of endo-2 (10 nmol) reduced endo-2 analgesic 
efficacy (closed circles)  compared with subjects injected with saline  (open circles), 
indicating induction of endomorphin-2 analgesic tolerance.  Saline-Pretreatment (white 
circles) ED50= 7.3 nmol (95% CI = 3.6 – 14.7 nmol). 
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Figure 2.6: Effects on AAV5-hADC pre-treatment development of endomorphin-2 
(Endo-2) tolerance in subjects pre-treated with normal IgG or anti-agmatine IgG.  
Analgesic dose-response curves to acute intrathecal Endo-2 challenge; 30 min following 
an acute intrathecal injections series of either Normal IgG + Endo-2 (open circles) or 
anti-agmatine IgG + Endo-2 (closed circles). A group of age-matched controls (blue 
circles) injected with saline paired to those injected with AAV5-ADC were injected 
saline and then endomorphin-2. Saline + Saline resulted in decreased acute Endo-2 
efficacy (blue circles). AAV5-hAD + Normal IgG did not result in development of 
analgesic tolerance to Endo-2 (Open circles). AAV5-hADC + Anti-Ag IgG treated 
subjects pre-treated with Endo-2 demonstrated reduced Endo-2 efficacy indicating that 
induction of acute Endo-2 analgesic tolerance did occur in this experimental group. 
AAV5-hADC+Normal IgG-Endo-2 (white circles) ED50= 1.9 nmol (95% CI = 1.3 - 2.8 
nmol). 
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Treatment Group Average Time on Rotarod (seconds) 
Saline - Saline 288 (270-305) 
Saline - Morphine 285 (265-304) 
AAV5-hADC – Saline 270 (243-296) 
AAV5-hADC - Morphine 278 (243-313) 
 
 
 
Table 2.4: Rotarod Motor Dysfunction: Comparison between treatment groups on  
performance in the rotarod assay of motor impairment.  
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DISCUSSION 
 
 The key observation in the present study is that intrathecal delivery of a viral 
vector carrying the gene for human ADC resulted in the prevention of the development of 
opioid analgesic tolerance in mice eight weeks post-injection. Expression of mRNA 
coding for the human ADC gene was found in cervical and lumbar spinal cord and dorsal 
root ganglia, as well as fourth ventricle choroid plexus, and periaqueductal grey (PAG). 
These results indicate that regions of the CNS that are known to participate in the 
development of opioid analgesic tolerance carried the target mRNA.  Therefore, it is 
feasible that agmatine was produced by the overexpressed enzyme resulting in outcomes 
that parallel the pharmacological studies of exogenous agmatine delivery to the 
intrathecal space.  
In order to pursue the identification of endogenous agmatine arising from the 
AAV-hADC treatments, we took an initial indirect approach.  An immunoneutralization 
strategy used scavenging antisera to determine whether endogenous agmatine accounted 
for the prevention of opioid tolerance observed in subjects treated with the AAV-hADC 
treatment. This method has been widely used to assess the effects of endogenous 
analgesic substances (Ohsawa et al., 2001; Tseng et al., 2000; Vanderah et al., 1994) and 
recently endogenous pro-nociceptive substances (Fairbanks et al., 2014). It was 
previously demonstrated that a structure-specific anti-agmatine immunoglobulin G (Anti-
Ag IgG) reversed the pharmacological effects of exogenously applied intrathecal 
agmatine (Wade et al., 2009). Therefore, it was reasoned that intrathecal administration 
of the Anti-Ag IgG antibody should similarly reverse the pharmacological effects of 
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endogenous agmatine presumed to be produced by the overexpression of hADC.  In fact, 
when immunoneutralizing antibodies selective for agmatine were delivered intrathecally, 
the magnitude of analgesic tolerance was significantly reduced. The selectivity of this 
effect for agmatine is indirectly supported by the observations that such a reduction was 
not observed with and intrathecal injection of normal IgG. Specifically, the lack of effect 
of the normal IgG indicates that Anti-Ag IgG reversal of the effect of AAV-hADC 
overexpression on analgesic tolerance is not an incidental effect of the normal IgG. 
Therefore, these observations support the proposal that elevated endogenous agmatine 
contributes to the anti-tolerance effect of the AAV5-ADC treatment.   
Agmatine, was discovered in the CNS in 1994, closely followed by the cloning of 
its synthetic (Morrissey et al., 1995) and degradative enzyme systems (Iyer et al., 2002) 
that are also expressed in CNS. Subsequently neuropharmacological investigations have 
converged on an inhibitory role in multiple models of behavioral neural plasticity (Piletz 
et al., 2013). Specifically, we and others have shown that agmatine also robustly inhibits 
the development of opioid-induced tolerance (Fairbanks and Wilcox, 1997; Kitto and 
Fairbanks, 2006; Kolesnikov et al., 1996; Morgan et al., 2002; Wade et al., 2008), but 
without motor toxicity (Fairbanks et al., 2000; Nguyen, 2003).  Consistently, in the 
present study, subjects receiving the i.t. injection of AAV5-hADC did not demonstrate 
altered performance in rotarod compared to control subjects at the time point assessed. 
It has previously been shown that agmatine inhibits NMDA-evoked current (Yang 
and Reis, 1999) and behavior (Roberts et al., 2005) as well as NO production (Galea et 
al., 1996). The collective prior indirect evidence suggests that agmatine likely acts 
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through antagonism of the NMDA receptor/NOS cascade. It has been established for over 
two decades that co-administration of NMDA receptor antagonists with opioids prevents 
the development of opioid tolerance (Trujillo and Akil, 1992). This strategy has been 
used clinically to “reset” a patient’s opioid analgesic efficacy and potency when opioid 
analgesic tolerance has arisen (Prommer, 2012; Quinlan, 2012). However, initial efforts 
to develop a combined preparation of opioid + NMDA receptor antagonist have not yet 
advanced to practice (Galer et al., 2005).  As stated previously, what distinguishes 
agmatine from other NMDA receptor antagonists/NOS inhibitors is that it is synthetized 
in vivo. Therefore, through a gene therapy approach such as described here, highly 
localized delivery at the site of maladaptive neuroplasticity becomes a possibility. 
Prior studies of the distribution of GFP labeling in spinal cord and DRG 
(Vulchanova et al., 2010) suggest that the AAV5 serotype used in these experiments 
differentially target sensory neurons. Specifically, there is preferential tropism for large 
diameter sensory neurons and small diameter CGRP- or SP-containing neurons.  
Additionally, we have demonstrated expression of GFP in various regions of the brain 
(Schuster et al., 2014), including the choroid plexus,  presumably from rostral diffusion 
of the viral particles.  Therefore, the mRNA expression data presented here are consistent 
with these prior gene expression distribution studies using the GFP marker.  
The tissues assessed for hADC expression merit speculation as to how they may 
participate in the observed prevention of opioid tolerance.  It is conceivable that if hADC 
is overexpressed in sensory neurons terminating in the dorsal horn of the spinal cord, or 
in intrinsic spinal neurons, the resultant elevation in agmatine production could act 
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similarly to that of exogenously injected agmatine in models of morphine tolerance 
(Fairbanks and Wilcox, 1997).  Additionally, the expression of hADC in epithelial cells 
of the choroid plexus could be participating in the elevation of agmatine via release of 
agmatine into the CSF.  This could cause a broad distribution of the molecule throughout 
the CNS that could act in a comparable manner as observed in prior pharmacological 
studies demonstrating efficacy of i.c.v. injected agmatine on morphine analgesic 
tolerance (Kitto and Fairbanks, 2006). In regards to the expression of hADC in the PAG, 
to our knowledge, there has not yet been an evaluation of agmatine microinjected into the 
PAG. It is also possible that hADC expressed in PAG could produce agmatine that could 
modify morphine antinociception. However, the PAG is less likely to be a locus for 
prevention of the development of opioid analgesic tolerance in light of previous evidence 
that microinjections of MK801 to the PAG does not impact development of morphine 
analgesic tolerance (Morgan et al., 2009). We cannot at this time determine whether 
expression in one particular region or another is primarily responsible for the effect of the 
treatment. Further work is needed to selectively transduce one region or one cell 
population to determine where the effect of hADC expression originates. Additionally, 
hADC expression may have taken place in a location that we have not probed that may 
also contribute to the observed effect. 
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SUMMARY & CONCLUSIONS 
 The present study features an application of gene transfer to sensory neurons, the 
midbrain, and choroid plexus epithelial cells using direct lumbar puncture. As gene 
therapeutics are developed, optimized, and considered for translation into clinical practice 
for   applications (Aubourg, 2013), an opportunity to intrathecally deliver gene therapy as 
an adjuvant to chronic opioid pharmacotherapy may be an effective pain management 
strategy. 
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Chapter 3. Quantification of agmatine in mice intrathecally injected with AAV5-hADC.  
 
CHAPTER SYNOPSIS 
 The data presented in Chapter 2 strongly support the proposal that the expression 
of human ADC following intrathecal delivery of viral vectors results in elevation of 
agmatine in spinal cord. In order to confirm that proposal it is necessary to determine 
whether tissue extracted from hADC-treated subjects contain elevated agmatine levels 
relative to controls.  The goal of this study was to optimize the existing HPLC 
quantification method of agmatine in order to enable such analysis of hADC-treated 
tissue. Until recently, detection of agmatine in mouse spinal cord has largely been elusive 
and confounded by excess levels of the metabolite of agmatine, putrescine. Based on the 
introduction of heat stabilization technology, and minor solvent modifications of the 
previously validated method by Roberts et al., (2007) we hypothesized that application of 
such an approach would improve detection of agmatine in mouse spinal cord. The impact 
of heat stabilization of tissue samples versus snap-frozen (liquid nitrogen) was evaluated 
in terms of both agmatine and putrescine detection (Figure 3.4). The final modified 
method described here was used to evaluate levels of agmatine in spinal cord tissue of 
mice receiving a single i.t. injection of AAV5-hADC.  
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INTRODUCTION 
 Agmatine, (4-(Aminobutyl)guanidine) is a small molecule that is synthesized 
from L-arginine by arginine decarboxylase (ADC) (Figure 3.1). First discovered in 1910 
by the Nobel laureate, Albrecht Koessel, in the pollen of Ambrosia artemisfolia, agmatine 
was primarily thought to be a constituent of bacterial and plant organisms. However, it 
was not until 1994 that agmatine was identified as an endogenous substance in the central 
nervous system by Donald Reis and colleagues at Cornell Medical college (Li et al., 
1994). Since then it has been demonstrated to have numerous properties that are 
suggestive of a neurotransmitter. Notably, agmatine appears to have an inhibitory impact 
on neuroplasticity (Piletz et al., 2013). These observations would suggest that agmatine is 
both measurable and manipulatable in the CNS. The present chapter focuses on a new 
strategy that overcomes challenges that we have observed in measuring picomol levels of 
agmatine in CNS tissues. The modifications to the previously validated method by J. 
Roberts (2007), improves detection level of agmatine and reduces the opportunity for 
putrescine, the metabolite of agmatine, to interfer with the stoichiometry of the 
derivatization reaction (Figure 3.2B).  
 The current understanding of the de novo synthesis of agmatine and putrescine in 
mammals is that L-arginine is converted to agmatine via arginine decarboxylase  (EC 
4.1.1.19) (Li et al., 1994; Regunathan and Reis, 2000). Agmatine is subsequently 
hydrolyzed by the enzyme agmatinase (EC 3.5.3.11) into putrescine (Figure 3.1) (Gilad et 
al., 1996; Sastre et al., 1996). It has been noted that human ADC is not the same as the 
ADC found in plants, bacteria or invertebrates (Molderings and Haenisch, 2012). A 
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partial clone of the human form of ADC was introduced in 1995 by Morrissey and 
colleagues (Morrissey et al., 1995). The human form of the putrescine enzyme, 
agmatinase, was cloned in 2002 (Iyer et al., 2002; Mistry et al., 2002). These enzymes 
have been shown to be differentially distributed in murine neuronal cell bodies (Zhu et 
al., 2004), glial cells hippocampus and cerebral cortex (Peters et al., 2013; Iyo, 2006).  
 
Agmatine Concentrations in Central Nervous System 
 The first studies of the tissue distribution of endogenous agmatine by Raasch et al, 
(1995) observed a concentration in extracted Sprague Dawley rat whole brain of 2.4 ng/g 
ww (18 pmol/g) (Table 3.1). Lung and stomach tissue respectively demonstrated 10- and 
50-fold greater agmatine. Such high levels in the stomach may be a result of the high 
content of agmatine found naturally in plant and food sources (Molderings and Haenisch, 
2012). The brain concentration was relative low compared to all other tissues but 5-fold 
greater than that detected in plasma. It was notable that a potential strain difference was 
observed between Long-Evans and Sprague Dawley rats with elevated concentrations of 
agmatine in Long Evan’s rat brain at specific time points (Table 3.1) (Raasch et al., 
1995). It is worth noting that we (Speltz-Paiz and Fairbanks, unpublished observations) 
and others (Yoon et al., 1999) have observed a significant reduction in the susceptibility 
of Long-Evans rats to establish nerve injury-induced hyperalgesia, which is also reduced  
by exogenous agmatine.  
 A different study quantified agmatine levels in cultured astrocytes of day old 
Sprague Dawley rats (Regunathan et al., 1995). The levels detected in isolated astrocytes 
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were greater than that observed in most rat brain samples (Table 3.1). Such an elevation 
could suggest that astrocytes are an important site of synthesis and/or storage of 
agmatine; alternatively, cultured astrocytes may not sufficiently reflect the in vivo 
condition and culture conditions may result in an elevated concentration of agmatine in 
the in vitro versus in vivo state. From our initial HPLC studies we reported detection of 
agmatine in mouse spinal cord at a level of 0.96 µg/g, substantively higher than in the rat 
(Fairbanks et al., 2000), which may reflect a species difference. It should be noted that 
the method used by Fairbanks et al. (2000) used naphthalene dicarboxaldehyde (NDA); a 
fluorescent compound that is more stable than ortho-phthalaldehyde (OPA) used in other 
methods and may have contributed to higher detectable levels of agmatine. However, our 
observations since the time of that publication suggest that putrescine may have also 
contributed to that result, a confound that will be discussed later. 
 Between 2002 and 2005 our research group conducted a study of spinally 
delivered agmatine to determine the spinal pharmacokinetic profile of exogenously 
delivered agmatine (Roberts et al., 2005). It was determined that the residence time of 
agmatine in spinal cord tissue significantly exceeds that of plasma. The half-life of 
agmatine in serum or plasma following systemic injection is typically on the order of 
minutes (Raasch et al., 2002; Nguyen et al., 2003; Piletz et al., 2003). However, the half-
life of intrathecally injected agmatine in spinal cord was calculated to be approximately 
12 hrs. This finding supports the concept that agmatine may be taken up into a cellular 
compartment (i.e. neurons or astrocytes) rather than effluxed to the systemic circulation. 
This posited pathway is supported by the work of Goracke-Postle and colleagues (2007b) 
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who have demonstrated transporter-dependent uptake of radiolabeled agmatine in both 
neurons and glia (Goracke-Postle, 2007a).  
During the time of the agmatine spinal pharmacokinetic study (Roberts et al., 
2005; Roberts, 2007), concern was raised in regard to the proximity of the eluted 
agmatine from putrescine peaks by the HPLC. It was suggested that many of the 
previously reported values in literature might have been attributable to putrescine rather 
than agmatine. Our bioanalytical studies have since been able to distinguish between 
agmatine and putrescine peaks in chromatographs by modifying the method from Roberts 
(2007) as described below.    
 
Challenges in Limit of Detection 
 In order to determine the impact of overexpressed human ADC in peripheral 
(dorsal root ganglion) and central (spinal cord, choroid plexus) nervous system tissues 
where we have confirmed mRNA expression, we previously attempted to analyze 
extracted tissues for agmatine content by the following methods: HPLC (Roberts et al., 
2005; Roberts, 2007) capillary electrophoresis (Song et al., 2004; Zhao et al., 2006), and 
liquid chromatography-tandem mass spectrometry (Song et al., 2004). All samples had 
been flash frozen (also called snap-frozen) by immersing the sample in liquid nitrogen 
and then storing in a -80°C freezer. 
 The previous HPLC-based attempts to quantify endogenous levels of agmatine in 
tissue samples that had been snap-frozen detected high quantities of putrescine (nmol/mg 
tissue), rather than agmatine, at the expected time peaks (Braun and Fairbanks, 
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unpublished observations). These observed levels of putrescine have been previously 
shown to interfere with the analysis (Braun and Fairbanks, unpublished observations). 
Therefore, our previous sample preparation and HPLC conditions were not able to 
reliably detect endogenous agmatine below the nanomol/mg tissue level. This matter has 
since been resolved by changing the mobile phase ratio from 65:35 acetonitrile (ACN): 
phosphate-buffered saline (PBS) to 80:20, and also by increasing the concentration of 
sodium cyanide (NaCN) and NDA used in the derivatization in Step 5 of the method in 
Figure 3.3. Agmatine and putrescine standards are now baseline separated (Figure 3.4). 
Slight variances in retention times (+/- 0.5 minutes) have been noted when switching to a 
new column however, the NDA-agmatine derivative is consistently eluted prior to NDA-
putrescine (Churchill and Fairbanks, unpublished observations).  
 When spinal cord or dorsal root ganglion (DRG) from individual or pooled 
AAV5-hADC-treated animals were extracted, snap-frozen, and then subsequently probed 
by capillary electrophoresis (CE), agmatine was not detected. Again, the metabolite of 
agmatine, putrescine, was detected (LOD = 15 nM) (Braun and Fairbanks, unpublished 
observations). Finally, attempts to measure agmatine by liquid chromatography-tandem 
mass spectrometry (LC-MSMS) (Song et al., 2004) resulted in two different confounds. 
The first was that of matrix-mediated signal suppression (Braun and Fairbanks, 
unpublished observations). A second confound was noted, that derivatized arginine 
spontaneously decarboxylated at the electrospray source and, therefore, was detected as 
agmatine by the multiple reaction monitoring (MRM) transitions (Braun et al., 
unpublished observations).  Therefore, these data indicate that future analyses by LC-
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MSMS should include diligent method development for separation of arginine and 
agmatine.  
 Taken together, these data suggested to us that the expected elevation in agmatine 
concentrations following treatment with hADC could have been ultra-localized and 
limited to the CNS tissue populations transduced (e.g., synaptic densities or extrasynaptic 
astrocytic structures). Thus, any elevation of endogenous agmatine arising from the 
AAV5-hADC treatment may have been degraded to concentrations below our limit of 
detection in the samples collected prior to the discussed modified method of Roberts 
(2007). 
 
Heat Stabilization 
 It is increasingly recognized that following conventional tissue extraction 
approaches (snap-freezing in liquid nitrogen, followed by -80°C storage), the extracted 
tissues are subject to rapid metabolism when thawing to room temperature, due to 
exposure to proteases and other protein metabolic enzymes (Goodwin et al., 2011). The 
measurement of analytes in conventionally collected tissue represent a mix of in vivo and 
ex vivo degradation products.  Therefore, the bioanalytical signature collected post-
mortem may not reflect the in vivo state and may result in significant sample variation or 
incorrect analyses (Svensson et al., 2009).  
 To address this confound, a technology was introduced to apply heat stabilization 
to freshly extracted tissues instead of snap freezing. The method of heat stabilization was 
introduced in 2009 (Svensson et al.) by a proteomics research group at Uppsala 
University. This group developed an instrument called the Stabilizor™ T1 (Denator AB, 
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Uppsala Sweden). The concept of the technology is that by rapidly and uniformly heating 
the freshly extracted tissue, degradation or metabolism is permanently and immediately 
stopped (Denator AB, 2014). Other researchers using this technology have found that 
treatment by heat stabilization with the Stabilizor™ T1 has prevented degradation of 
peptides in CNS tissue allowing for higher identification rates of murine brain 
neuropeptides such as met- and leu-enkephalin and dynorphin A and B in rat dorsal 
striatum (Petruzziello et al., 2013). Karlsson et al. (2013) detected 103 peptides, which 
included substance P, neurokinin and VGF in neonatal rat striatum that were not formerly 
detectable with snap-frozen tissues.  Zhang et al. identified 206 peptides in a single 
mouse brain (2012). These peptides included neurotensin, neurokinins, enkephalins, and 
neuropeptide Y, among others (Zhang et al., 2012). In work by Colgrave and associates, 
the profiling of neuropeptides in bovine hypothalamus determined that heat stabilization 
with the Stabilizor™ T1 reduced interference of endogenous peptide determination 
because it prevented degradation of peptides, thereby reducing the amount of peptide 
fractions in the sample matrix (2011). Spinal cord analysis by Su et al. (2014) discovered 
36 full-length, well-characterized neuropeptides such as enkephalins, nociceptin and 
neoendomorphins. Additionally, 118 novel spinal neuropeptides were identified as a 
result of implementing this new technology into their sample preparation method (Su et 
al., 2014). 
 This technique has also been used for the detection of small molecules in mouse 
brain such as: raclopride (347.2 g/mol) (Goodwin et al., 2011; Goodwin et al., 2012), 
adenosine triphosphate (MW = 507.18 g/mol), adenosine diphosphate (MW = 427.2 
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g/mol) and adenosine monophosphate (MW = 347.2 g/mol) (Blatherwick et al., 2013). 
Therefore, it was posited that this instrument could be used on our extracted mouse spinal 
cord to prevent the decomposition of agmatine into putrescine.    
 
MATERIALS AND METHODS 
Animals  
 All of the experiments were approved by the University of Minnesota’s 
Institutional Animal Care and Use Committee. Experimental subjects were Institute of 
Cancer Research (ICR) male mice (21-30 grams). Subjects were housed in groups of 4 
mice per cage in a temperature- and humidity-controlled environment and maintained on 
a 12 hour light/dark cycle with free access to food and water. 
Intrathecal injections 
 Agmatine and putrescine were purchased from Sigma Chemical (St. Louis, MO) 
and diluted in 0.9% NaCl. AAV5-hADC, agmatine, putrescine, or saline were 
administered intrathecally (i.t.) by direct lumbar puncture in conscious mice as described 
for mice by Hylden and Wilcox (1980). Briefly, the subjects were gently gripped by the 
iliac crest and a 30-gauge, 0.5 inch needle (mice) connected to a 50-µL Luer-hub 
Hamilton syringe was used to deliver injectate into the intrathecal space.  In the case of 
viral vector injection, a modified needle, catheter, syringe apparatus was used to inject 10 
microliters of injectate as described in Chapter 2 in order to conserve product.  
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Heat Stabilization vs. Snap-Freezing Comparison Study 
 To determine the effects of heat stabilization versus that of snap-freezing, a 
comparison study was performed (Figure 3.5). A total of 26 mice (ICR, Harlan, WI) of 
the same age and weight (21- 24 grams) were used. Ten animals were given a 5µl 
intrathecal (i.t.) injection of either sterile agmatine (120 nmol/5µl) or putrescine (120 
nmol/5µl). Additionally, six animals were given injections of sterile saline i.t. as controls. 
Each animal was then sacrificed 1 minute post-i.t. injection and spinal cord harvested via 
hydraulic extrusion using a blunt-edged needle and syringe with cold 0.9% saline (Meikle 
and Martin, 1981). Immediately post-extraction, half of the samples were snap-frozen and 
the remaining half was heat-stabilized using the Denator Heat Stabilizer™ T1 (Uppsala, 
Sweden). For clarification, snap-frozen samples were processed by immediately placing 
the extracted spinal cord in a 1.5 ml sample vial plastic and submerging it in liquid 
nitrogen.  The sample in the vial was placed in the -80 °C freezer until day of HPLC 
analysis.  Heat-treated samples were placed onto specially designed cartridges 
(Maintainor® Tissue, Denator AB) and processed using the default “Quick Fresh 
Compress” method on the Stabilizor™ T1 instrument. This method uses vacuum to 
evacuate air from the sample area (5-10 mbar) and compresses the sample between two 
heating plates, and rapidly heats the sample to 90°C (does not exceed 95°C). This process 
takes less than 30 seconds to complete. The heat-treated samples remain in the cartridges 
and are placed in the -80°C until the day of HPLC analysis. 
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Tissue Preparation for the Comparison Study 
 The day of HPLC analysis, the samples were removed from -80°C storage and 
10-25 mg of spinal cord was weighed in a new 1.5 ml sample vial and prepared for 
derivatization and injection onto the HPLC according to the method outlined in Figure 
3.3. Briefly, the samples were acid-precipitated with perchloric acid (150 µL, 0.6 N) and 
hydrochloric acid (65µL, 0.1 M in methanol) and allowed to sit on ice for 30 minutes. 
After 30 minutes, the solution was neutralized with KOH (4.2M) to a pH of 
approximately 7.0-7.5 by dotting on pH paper. Once neutralized, the samples were 
centrifuged (Eppendorf, Model: 5415 D) at 10,000 rpm (9280 x g) for 15 minutes. 
Approximately 280 µL of the aqueous phase was transferred to a second set of 1.5 ml 
vials and allowed to sit over night in the -20°C freezer. The next day, the samples were 
centrifuged at 10,000 rpm (9280 x g) for 15 minutes. A salt pellet from the neutralization 
formed in the bottom and 250 µL of the aqueous phase was transferred to a third set of 
vials. This final supernatant was finally concentrated to dryness by vacuum centrifugation 
(Savant, Speed Vac® Model: SC100).  
 
HPLC Analysis for the Comparison Study 
 The dried and concentrated samples from the aforementioned procedure were re-
suspended in 100 µL borate buffer (pH 9.4) and derivatized with sodium cyanide (100 
µL, 0.025 M) and naphthalene dicarboxaldehyde (NDA, 200 µL, 0.01 M in methanol). 
This solution was allowed to react at room temperature for approximately 30 minutes, 
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producing an agmatine-NDA derivative of high fluorescence and stability for HPLC 
analysis (Hewlett-Packard, 1100 Series).   
 An injection volume of 20 µL was used for all samples and standards at 25°C 
(Hewlett-Packard Column Bank Model: G1316A and Autosampler Model: G13129A) 
and injected onto a 250 x 4.6 mm, Alltima C8, 10 micron column (Grace Davison 
Discovery Science, Deerfield, IL) at a flow rate of 1.5 mL/min (Hewlett Packard, 
Quaternary Pump Model: G1311A). The mobile phase consisted of 80% acetonitrile 
(HPLC Grade): 20% phosphate-buffered saline (3.42 g monopotassium phosphate and 
4.32 g dipotassium phosphate in 1 L H2O) (pH: 6.81) and was filtered prior to every run 
or sequence through a 0.44 µm nylon filter.  A degasser unit  (Hewlett-Packard Model: 
G1322A) was also employed. 
 The fluorescence intensity of NDA-agmatine and NDA-putrescine derivatives 
were recorded over time using an excitation wavelength of 249 nm and an emission 
wavelength of 466 nm (Hewlett-Packard Model: 1046A). Agmatine and putrescine 
standards were run concurrently in order to obtain the most accurate estimates of tissue 
and serum agmatine concentrations. Evaluation of peak retention time and peak area was 
conducted with the HP Chemstation software (Ver. 10.02). During method refinement, 
external spikes of agmatine standards were employed to verify the NDA-agmatine peak 
in the chromatograph (Figure 3.6).  
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Modified HPLC Analysis of Agmatine in Mice Receiving AAV5-hADC 
 Early HPLC method development evaluated different ratios of mobile phase  
(acetonitrile (ACN) and phosphate-buffered saline (PBS)) and their effect on agmatine 
and putrescine standard retention time and peak area. It was determined that a ratio of 
80:20 ACN:PBS achieved consistent baseline separated peaks for agmatine and 
putrescine (Figure 3.4) (Churchill and Fairbanks, unpublished observations). Thus, all 
work described here uses the 80:20 ratio for the mobile phase, not the 65:35 as described 
by Roberts et al. (2005), regardless of tissue preparation technique. 
 Only in the studies quantifying agmatine levels in AAV5-hADC-treated tissue, 
was the Stabilizor™ T1 used to prepare extracted spinal cords, instead of snap-freezing, 
in order to inactivate any metabolic activity that could potentially degrade agmatine to an 
undetectable level. In addition to using heat stabilization, the aforementioned HPLC 
method was also modified when analyzing the tissue from the AAV5-hADC study 
(Chapter 2, Figure 2.2) by excluding methanol from the reagents and solvents used in the 
tissue preparation. Specifically the 0.1M HCl solution in methanol was omitted and the 
NDA was dissolved in acetonitrile to prevent methanolysis of our primary analyte, 
agmatine. Therefore it was determined collectively that the heat stabilization of the tissue, 
coupled with the combination of the modified mobile phase, and removal of methanol 
from the derivatization step, would prevent degradation of agmatine, our compound of 
interest, thereby enabling the detectability of agmatine in mice spinal cord tissue. 
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RESULTS 
Heat Stabilization vs. Snap-Freezing Comparison Study 
 A primary goal of the study was to determine whether heat stabilization improved 
the limit of detection for agmatine in our HPLC-based bioanalytical assay.  To address 
this question we conducted a study to compare mouse spinal cord levels of agmatine and 
putrescine where the extracted samples were either snap-frozen (liquid nitrogen) or heat-
stabilized (Stabilizor™ T1) (Figure 3.5).  Because the previous HPLC method had been 
shown to detect levels of injected agmatine i.t. (Roberts et al., 2005), it was decided for 
this study to inject agmatine (120 nmol), putrescine (120 nmol) or saline by direct lumbar 
puncture. Spinal cord tissue was extracted and collected 1 minute post-injection.  
 Figure 3.7A shows agmatine levels in spinal cords treated with either of the 
aforementioned treatments.  The first two bars illustrate that agmatine detection was 
approximately the same in snap-frozen or heat-treated samples treated with exogenous 
agmatine. Average values for bars 1 and 2 (“i.t. Ag-Snap” and “i.t. Ag-Heat”) were 0.036 
nmols/mg tissue and 0.036 nmol/mg tissue, respectively. Bars 3 and 4 (“i.t. Put-Snap” 
and “i.t. Put-Heat”) show that apparent reduction of agmatine was not statistically 
significant in heat-treated subjects as compared to those samples that were snap-frozen. 
The average agmatine value for snap-frozen (putrescine i.t.) was 0.0045 nmol/mg tissue 
and 0.0010 nmol/mg tissue in heat-treated (putrescine i.t.). Finally, bars 5 and 6 (“i.t. 
Saline-Snap” and “i.t. Saline-Heat”) illustrate a limited detection of endogenous agmatine 
in spinal cords from mice intrathecally injected with saline regardless of snap-freezing or 
heat-treatment. The average agmatine in snap-frozen (saline i.t.) was 0.00065 nmol/mg 
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tissue. The average agmatine value in heat-treated, (saline i.t.) was 0.00098 nmol/mg 
tissue.  
 Figure 3.7B depicts spinal putrescine levels in spinal cords treated with one of the 
three aforementioned treatments. The first two bars (“i.t. Ag-Snap” and “i.t. Ag-Heat”) 
illustrate that putrescine detection was significantly reduced (Student’s t-test, p<0.005) in 
heat-treated samples compared to snap-frozen samples that were treated with i.t. 
agmatine. The average putrescine value for snap-frozen (agmatine i.t.) was 0.11 nmol/mg 
tissue and 0.0.039 nmol/mg tissue in heat-treated (agmatine i.t.). Bars 3 and 4 (“i.t. Put-
Snap” and “i.t. Put-Heat”) show that the apparent reduction of putrescine was not 
statistically significant in heat-treated samples as when compared to those that were snap-
frozen that were treated with exogenous putrescine. The average putrescine values for 
snap-frozen and heat-treated (putrescine i.t.) were 0.27 and 0.14 nmol/mg tissue, 
respectively. Finally, bars 5 and 6 (“i.t. Saline-Snap” and “i.t. Saline-Heat”) illustrate a 
limited detection of endogenous putrescine in spinal cords from mice intrathecally 
injected with saline regardless of snap-freezing or heat-treatment. The reduction of 
putrescine in heat-treated (saline i.t.) was statistically significant (Student’s t-test, p<0.05) 
when compared to snap-frozen (saline i.t.). The average putrescine values for snap-frozen 
and heat-treated (saline i.t.) were 0.468 and 0.061 nmol/mg tissue, respectively. The 
levels of exogenously delivered agmatine in spinal cord tissue seemed unaffected by heat 
stabilization; however, heat-treatment reduced putrescine in the sample matrix, whether 
derived from the conversion of agmatine by agmatinase, or by other degradative 
processes. This was interpreted as an improvement for our method development. 
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Therefore, this instrument was used to preserve all subsequent tissue extractions, 
including those from the AAV5-hADC studies. It was expected that with less putrescine 
present in the tissue sample, the derivatization reaction in Figure 3.2B would enable all 
agmatine to be labeled with NDA. Any agmatine present would not have to compete with 
high levels of putrescine to be reacted with NaCN and labeled with NDA.  
 
Acetonitrile vs. Methanol: Influences on Agmatine Detection  
 Prior to the presentation of the bioanalytical results from the AAV5-hADC study, 
it is valuable to present an additional refinement that has been made to the HPLC method. 
After extensive literature review on previous agmatine detection via HPLC-fluorescence, 
it was discovered that the labile nature of agmatine might be due in part to decomposition 
by methanolysis (Wehr, 1995). That is, when agmatine is in the presence of methanol, 
agmatine  can readily break into fractions (Wehr, 1995).  
 Previous to this finding, all tissue samples had been processed with methanol in 
two different steps of the method described in Figure 3.3. First in step 2, the acid 
precipitation step, a solution of perchloric and hydrochloric acid in methanol is used. 
Second, methanol is used in the fifth step (Figure 3.3.) to dissolve the fluorescent label 
for primary amines, napthalene dicarboxyaldehyde (NDA). It was a concern that perhaps 
previous attempts to detect agmatine in samples had been subject to methanolysis as 
described by Wehr (1995). To quickly compare the influence of methanol on the 
detection of agmatine, an experiment was conducted using agmatine and putrescine 
standards in water. One set of standards was made for each compound and divided in 
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half. One half to be prepared using methanol and the other half to be prepared with 
acetonitrile (HPLC grade). Acetonitrile was chosen due to similar polarity as methanol.  
 The peak area and concentration were plotted and the R-squared values and peak 
area were compared (Figure 3.8). The standards that used methanol in their preparation 
had the following R2 values: 0.848 for agmatine and 0.994 for putrescine. The standards 
that used acetonitrile instead of methanol had the following R2 values: 0.995 for agmatine 
and 0.975 for putrescine. It was also observed that the agmatine standards that used 
acetonitrile had slightly less peak area compared to the same standards that used 
methanol (Figure 3.8). Peak areas in the putrescine standards were also lower in the 
acetonitrile group as compared to the those derivatized with methanol. These results 
suggest that with the current column and modified HPLC method, a methanol-free 
sample preparation would yield more accurate detection of agmatine.  
 
Heat-Stabilized Assessment of Agmatine in hADC-Treated Mice  
 Based on the previous results, it was decided that the HPLC method would be 
modified when analyzing the tissues collected from animals in the AAV5-hADC studies. 
For all studies of tissue extracted from AAV5-hADC treated subjects, the method would 
be refined to use the Stabilizor™ T1 at the time of tissue collection and the subsequent 
sample preparation and derivatization of the tissue would be conducted in a methanol free 
manner. The combination of using the Stabilizor™ T1 and acetonitrile (instead of 
methanol) would reduce levels of putrescine from the sample matrix and eliminate any 
possibility of methanolysis of agmatine. These two changes assisted in enabling lower 
levels of agmatine to be more detectable.  
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 To determine whether hADC expression resulted in increased levels of agmatine 
in tissue, we hydraulically extruded and heat-treated the spinal cords from mice treated 
with AAV5-hADC (n=14) and saline-treated controls (n=6). Only the cervical portion of 
the spinal cord was analyzed by HPLC because in several cohorts, more mice appeared to 
have hADC expression in the cervical spinal cord region. These mice were among those 
used for the studies conducted in Chapter 2. Consistent with the hypothesis, the cervical 
spinal cords of mice that had received AAV5-hADC pre-treatment contained 
significantly higher levels of agmatine than their saline counterparts (Student’s t-test 
p<0.05) (Figures 3.9 and 3.10).  
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Figure 3.1: Agmatine pathway: Agmatine is synthesized by converting L-arginine via 
arginine decarboxylase (ADC) into agmatine and agmatine is metabolized by agmatinase 
(AGM) into putrescine. 
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Figure 3.2: (A) Derivatization reaction of napthalene dicarboxaldehyde (NDA) to the 
primary amine group of agmatine in the presence of cyanide. (B) Insufficient 
concentration of NDA and cyanide could cause a confound with the mono-derivative of 
NDA-putrescine since it will have a similar retention time as the NDA-agmatine. This 
method provides excess NDA and cyanide to prevent this from happening. 
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Tissue Species 
(n) 
Reported 
Concentration 
(ng/g ww) 
 
Conversion to 
pmol/g ww 
(Based on mw 
of 130.192) 
Detection 
Method 
Reference 
Rat Brain 
(Region     
not noted) 
Sprague 
Dawley, 
5 months 
2.40 ± 0.60 
 
18 HPLC, 
OPA 
Derivatization 
Raasch et al., 
1995 
Rat Brain 
Cortex 
Long Evans 
3 months 
1.25 
 
 9.6 
HPLC, 
OPA 
Derivatization 
Raasch et al., 
1995 
 Long Evans 
14 months 
1.55 11.9 
HPLC, 
OPA 
Derivatization 
Raasch et al., 
1995 
 Long Evans 
24 months 
8.3 63.7 
HPLC, 
OPA 
Derivatization 
Raasch et al., 
1995 
Rat Brain 
Cerebellum 
Long Evans 
3 months 
1.06 8.14 
HPLC, 
OPA 
Derivatization 
Raasch et al., 
1995 
 Long Evans 
14 months 
1.45 11 
HPLC, 
OPA 
Derivatization 
Raasch et al., 
1995 
 Long Evans 
24 months 
9.4 72.2 
HPLC, 
OPA 
Derivatization 
Raasch et al., 
1995 
Cultured 
Primary 
Astrocytes 
Sprague 
Dawley 
Postnatal 
Day 1 
8.5 65 HPLC, 
OPA 
Derivatization 
Regunathan et 
al., 1995 
Mouse  
Spinal Cord 
Mouse  
ICR-CD1 
 
0.96 ±  0.14 
(micrograms/ 
gram) 
 
7300 HPLC, 
NDA 
Derivatization 
Fairbanks     
et al., 2000 
 
 
Table 3.1: Levels of endogenous agmatine in murine tissues of the central nervous 
system. (Abbreviations: OPA, ortho-Phthaladehyde; NDA, naphthalene dicarboxyaldehyde;  
ww; wet weight) 
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Figure 3.3: Overview of tissue preparation and derivatization of sample for HPLC 
analysis. (Abbreviations: MeOH, methanol; NDA, napthalene dicarboxaldehyde)  
 
 
 
 
 
 
1. Weigh 10-25 mg of Frozen Tissue, Add  0.1% Triton-X & 
 Homogenize with Ultrasonic Cell Disruptor (Branson, Sonifier®) 
2. Acid Precipitate Tissue/Mixture from Step 1  
with HClO4 & HCl (MeOH) 
3. Neutralize Sample Matrix , Centrifuge,  
&  Collect Supernatant 
4. Speed Vac to Dryness 
5. Derivatize (30 minutes):  
Sample + 100 ul Borate Buffer (pH = 9.4)  
+ 200 ul NDA (in MeOH) + 100 ul NaCN 
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Figure 3.4: Chromatographs of agmatine and putrescine standards in water. Standards 
were derivatized with excess sodium cyanide (NaCN) and NDA and run with a mobile 
phase of 80:20 acetonitrile (ACN): phosphate-buffered saline (PBS). For this particular 
sequence, on this particular column, the average retention times for the NDA-agmatine 
derivative was 7.6 minutes and 10.1 minutes for the NDA-putrescine derivative. 
Agmatine standards in the chromatograph are in order of decreasing concentration: 12.5, 
6.25, 3.125, 1.5625 and 0 picomols/injection. Putrescine standards in the chromatograph 
are also in order of decreasing concentration: 200, 100, 62.5, 25, and 0 
picomols/injection.  
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Figure 3.5: Comparison Study Overview. Mice were given an inrathecal (i.t.) injection of 
(sterile) agmatine, putrescine or saline. Half of the samples were snap-frozen by 
submersion in liquid nitrogen whereas the other half was heat-stabilized with the 
Stabilizor™ T1 Instrument.  
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(n=6) OR  OR  
Snap Frozen 
with liquid Nitrogen  
Agmatine (n=5) 
Putrescine (n=5) 
Saline (n=3) 
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Agmatine (n=5) 
Putrescine (n=5) 
Saline (n=3) 
OR  
HPLC – Fluorescence 
Compare agmatine & putrescine values 
between treatment groups  
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Figure 3.6: Representative chromatographs of A) spinal cord tissue spiked with agmatine 
B) spinal cord tissue with no agmatine spike and C) agmatine standard in water (12.5 
picomols/injection). The sample of spinal cord that was spiked with agmatine (A) has an 
approximate peak retention time of 7.8 minutes. This is comparable to the retention time 
of the peak of agmatine standard in water (C) that was also approximately 7.8 minutes. 
The spinal cord that received no agmatine spike (B) showed no detectable amounts of 
agmatine.  
 
 
A) Spinal Cord 
Sample with 
Agmatine Spike 
B) Spinal Cord 
Sample  
(No Spike) C)Agmatine  Standard 
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Figure 3.7: Comparison Study: Snap-Frozen Spinal Cord vs. Heat-Stabilized Spinal 
Cord. (A) Levels of agmatine were not significantly different across groups and tissue 
preparation technique. (B) Levels of putrescine were decreased using the heat treatment 
technique in animals receiving i.t. agmatine and i.t. saline, but not i.t. putrescine. 
(significant difference **p<0.005 and *p<0.05, Student’s t-test) Methanol used in 
preparation and derivatization. 
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Figure 3.8: Agmatine and putrescine standards derivatized with NDA in methanol (top) 
or acetonitrile (bottom) for 30 minutes then injected onto HPLC.  
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Figure 3.9: Agmatine levels in heat-protected cervical spinal cord were elevated in 
AAV5-hADC treated mice relative to saline-treated controls. Sample preparation and 
derivatization was methanol free. (*significant difference; p<0.05, Student’s t test)  
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Figure 3.10: Chromatographs from AAV5-hADC Study: A) Overlay of spinal cord 
tissue; animal treated with AAV5-hADC i.t. (red), animal treated with saline i.t. (green), 
and agmatine standard (3.125 picomols/injection) (blue). Square represents region where 
agmatine standards elute (retention time of 5.5 minutes).  B) Enlargement of enclosed 
area at 5.5 minutes from panel A: spinal cord from an animal treated with AAV5-hADC 
i.t. (red), spinal cord from an animal treated with saline i.t. (green) and the 3.125 
picomol/injection standard (blue) C) Overlay of agmatine standards in order of 
decreasing concentration: 25, 12.5, 6.25, 3.125 and 0 picomols/injection. 
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DISCUSSION 
Heat-Stabilizing vs. Snap-Freezing 
 Typical tissue harvesting involves “snap-freezing” of extracted tissue. This is 
frequently performed by submerging samples in liquid nitrogen or dry ice to stop any 
metabolic processes taking place in the extracted tissue. The goal is to preserve the 
extracted tissue in a state that is as close as possible to the in vivo environment. An 
alternative to snap- freezing samples is to denature proteins and enzymes by heating, such 
as with microwave (O'Callaghan and Sriram, 2004). Laboratory microwaves and their 
animal retainers are specifically designed for rapid preservation of the intact murine 
brain, and would not accommodate spinal cord preservation. Currently, there is no such 
device for microwaving spinal cord in vivo (personal correspondence with manufacturer, 
Ugo Basile). 
 Prior to 2009, instrumentation for the preservation of murine spinal cord tissue or 
other tissue and organs (up to 7 mm in thickness) was not available. Denator AB, has 
filled this gap in technology with their Heat Stabilizer™ T1 instrument. For this research, 
the mouse spinal cord was hydraulically extruded (Meikle and Martin, 1981) and 
immediately placed onto specially designed cartridges (Maintainor® Tissue). This 
cartridge is placed in a holder on the Stabilizor™ T1 instrument. Once the start button 
has been pressed, air is evacuated from sample area and the instrument proceeds to 
rapidly heat denature the sample. A Mass Spectrometry Imaging study has shown a 
significant difference in (AMP) and (ATP) levels in brain preserved via snap-freezing 
versus heat-stabilized (Goodwin et al., 2011; Goodwin et al., 2012). This difference is 
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believed to be due to the metabolic enzymes and proteins that resume their degradation 
activity when the sample is removed from -80°C, thawed, and the temperature increases. 
Consequently, ATP levels are elevated in heat-stabilized relative to snap-frozen and, as 
expected, AMP levels are reduced in heat-stabilized compared to snap-frozen. Rapid 
degradation has been reported to take place in snap-frozen samples in intervals as short as 
5 minutes at room temperature (Goodwin et al., 2011).  
 For a molecule such as agmatine, the concern with snap-freezing and thawing of 
tissue samples, is that agmatine could readily be metabolized into putrescine via 
agmatinase. Therefore, in hopes of optimizing the HPLC limit of detection of agmatine in 
mouse spinal cord, a comparison study between snap-frozen (liquid nitrogen) and heat- 
stabilized (Stabilizor™, Denator AB, Uppsala, Sweden) samples was conducted (Figure 
3.5). This study was conducted by exogenously delivering agmatine (120 nmol/5 µL) or 
putrescine (120 nmol/5 µL) or saline by direct lumbar puncture. These values were 
chosen based on previous data showing reliable HPLC detection of exogenously 
delivered agmatine (Roberts, 2005; Roberts, 2007). It must be noted, that this comparison 
study used the tissue preparation and sample derivatization that included the use 
methanol, therefore the levels of agmatine reported in the heat-treated vs. snap-frozen 
study (Figure 3.7) may be lower than actual values due to methanolysis as described 
below in the next section. This may explain why there were no statistically significant 
differences in agmatine concentration following exogenous delivery of i.t. agmatine, 
putrescine or saline, between heat-stabilized and snap-frozen treatment. It could also be 
that the high concentration of i.t. agmatine resulted in higher, overall concentrations of 
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detectable agmatine, potentially obscuring any loss due to metabolism. Another 
consideration is that the degradation of endogenous L-arginine into agmatine was 
contributing to overall agmatine levels in the snap-frozen samples. In future studies, the 
use of i.t. injected L-arginine would be of interest to confirm the endogenous capability 
of overexpressed arginine decarboxylase to generate agmatine.  
 Although there were no discernable differences in the agmatine levels between 
heat-treated or snap-frozen, this study did reveal that two groups of snap-frozen tissues 
had statistically significant more putrescine, the metabolite of agmatine, than the heat-
stabilized samples (Figure 3.7B). This was observed in the i.t. agmatine and i.t. saline 
groups. It was somewhat surprising that the levels of putrescine in snap-frozen, i.t. saline 
animals were greater than that of both snap-frozen and heat-treated i.t. putrescine. 
However, this may be attributable to the lower group size for the i.t. saline animals  (n=2 
for snap-frozen; n=3 for heat-treated) than in the i.t. agmatine and i.t. putrescine animals 
(n=5 for all groups). Levels of putrescine, overall, were higher in snap-frozen samples. 
Since putrescine is a natural compound that occurs in necrotic tissue, it could be that 
other decompositional pathways are contributing to the increased levels of putrescine in 
the all snap-frozen tissue.  
 The key finding of this study was that heat stabilization significantly reduced 
concentrations of spinal putrescine following exogenous delivery of agmatine, 
presumably derived from the metabolism of exogenously delivered agmatine. One might 
have expected that concentrations of spinal agmatine following exogenous delivery of 
agmatine may have been elevated in the heat-treated versus snap-frozen samples in 
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Figure 3.7A, but it may be that the excessive concentrations of agmatine delivered 
spinally obscured a detectable difference. From that point on, the Denator Stabilizor ™ 
T1 would be employed to treat freshly extracted tissues. It was posited that if the 
metabolism or degradation of agmatine could be stopped, the levels of agmatine might 
become detectable with the HPLC method. At the very least it would reduce the amount 
of putrescine that would compete for derivatization in step five of the HPLC method. 
This leads to discussion of the second modification made to the HPLC method.  
 
Methanolysis Prevention 
 When searching the literature regarding quantification and derivatization of 
agmatine, it has been described as labile (Satriano, 2004) and even “irreproducible” 
(Wehr, 1995). Precipitation of proteins in the biological sample with perchloric acid 
(PCA) in step one (Figure 3.3) is a common technique employed with biological tissue 
samples (Hanai, 1991). Not only does the PCA technique remove proteins, it also creates 
a stable environment for small molecules (Hanai, 1991). Other researchers quantifying 
agmatine in biological tissues have also used this technique routinely (Li et al., 1994; 
Regunathan et al., 1995; Feng et al., 1997; Rawls and McGinty, 1997; Hockl, 2000).   
  Research on the quantification of agmatine is abundant when analyzing this 
molecule in bacteria or plants. The most well known technique for agmatine detection in 
plants is by Flores and Galston (1982). Even in the plant system, issues of interfering 
amines and resolution of agmatine existed (Slocum et al., 1988; Slocum et al., 1989). 
Further investigation into the issues of agmatine quantification in plants revealed that 
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agmatine undergoes rapid methanolysis if the derivative is dissolved in methanol (Wehr, 
1995). Methanolysis is the process of exchanging the organic group of an ester with the 
organic group of an alcohol. The author also notes this as the main reason why previous 
studies of agmatine quantification (in plants) have largely been irreproducible (Wehr, 
1995).  
  The HPLC method published by Roberts et al. (2005 and 2007) were based on a 
combination of the following published methods. The isocratic mobile phase for HPLC 
(Feng et al., 1997), the acid precipitation of the biological tissue (Raasch et al., 1995) and 
finally the use of the more stable fluorescent compound naphthalene-2,3-
dicarboxaldehyde (NDA) in the derivatization step (De Montigny, 1987). In the presence 
of cyanide, NDA will react with primary amines such as agmatine and putrescine (Figure 
3.2A). It should be noted, that an excess of both the cyanide ion and NDA is required to 
push the derivatization process to full labeling of both primary amines of putrescine 
(Figure 3.2B). If insufficient amounts of NDA and cyanide are used in the derivatization, 
it is possible to have a monoderivative of NDA-putrescine which can be a confound with 
the NDA-agmatine derivative since they would have a similar retention time. Thus, 
excess levels of NDA (0.01 M) and NaCN (0.025 M) are recommended to label both 
amines sites on the putrescine molecule (Figure 3.6B) resulting in a longer retention time 
than the NDA-agmatine derivative Figure 3.4.  
 Comparing these publications to the HPLC methods developed by Roberts (2005 
and 2007) the following similarities and differences were noted. For the acid-preparation 
step, Raasch (1995) used a combination of 0.6N Perchloric acid (HClO4) and 0.1N 
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hydrochloric (HCl) acid in methanol. This is consistent with both the publication by 
Roberts et al, (2005) and the thesis work by Roberts (2007). Feng (1997) uses an isocratic 
technique for mobile phase elution. This is also consistent with both Roberts et al. (2005) 
and Roberts (2007). In the derivatization by De Montigney (1987), NDA was dissolved 
in acetonitrile. Yet, the method used by Roberts in his thesis (2007), NDA in methanol 
was used. Therefore, it was posited that the preparation and derivatization of tissue 
samples that involved methanol may have degraded agmatine in a similar manner as 
described by Wehr (1995) in their plant agmatine quantification. 
 In the study comparing a series of NDA-derivatized standards with and without 
methanol (figure 3.8), the  R2 value for agmatine was improved with the use of 
acetonitrile instead of methanol. Additionally, overall lowered putrescine peak area was 
observed when using acetonitrile. Agmatine, specifically in brain tissue has also been 
said to be subject to “overcrowding” in detection methods (Raasch et al., 1995); that is to 
be lost among the numerous amines present in a biological tissue sample. Since the goal 
of our analysis is to improve agmatine detection, using acetonitrile instead of methanol, 
would lower interference of putrescine and also yield more confidence in the linearity of 
our standards.  Thus, the decision was made to use NDA dissolved in acetonitrile and 
remove the HCl in methanol from the acid precipitation step when determining levels of 
agmatine in animals treated with AAV5h-ADC.  
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Quantification of Agmatine with Modified Sample Preparation & Derivatization 
 With the new HPLC tissue preparation technique and removal of methanol from 
the chemical matrix, the tissues from animals treated with AAV5-hADC were processed 
and evaluated for agmatine levels. Agmatine levels in heat-protected cervical spinal cord 
were elevated in AAV5-hADC injected mice relative to saline-treated controls and 
statistically significant (p<0.05, Student’s t test) (Figure 3.7).  Therefore, these 
observations support the proposal that elevated endogenous agmatine contributes to the 
effect of the AAV5-ADC treatment to protect against opioid-induced analgesic tolerance 
featured in Chapter 2 of this thesis  
 
SUMMARY AND CONCLUSIONS 
Taken together, these results indicated that heat stabilization, applied to reduce 
post-mortem metabolism of extracted tissue, may enable better detection of agmatine in 
CNS tissue at the picomol/mg tissue level.  Agmatine is known to have other therapeutic 
effects, thus, the heat stabilization approach may be important or valuable to other 
investigations of endogenous or exogenous agmatine effects in other forms of 
maladaptive neuroplasticity (e.g. learning and memory, stroke, spinal cord injury).  
 We have demonstrated that heat stabilization of extracted spinal cord reduces 
spinal cord putrescine concentrations following either agmatine or putrescine intrathecal 
injection. This procedure may be essential to prevent post-mortem metabolism of 
agmatine to its primary metabolite, putrescine. Our previous studies using liquid nitrogen 
mediated flash frozen post-mortem processing failed to sufficiently and reliable detect 
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and/or distinguish agmatine whether evaluated by HPLC, capillary electrophoresis, or 
mass spectrometry.   Heat stabilization has enabled us for the first time to reliably detect 
agmatine in the spinal cord at the picomol/ mg tissue level via HPLC and, importantly, to 
demonstrate that a single intrathecal injection of AAV vector carrying the gene for 
arginine decarboxylase results a significant elevation agmatine concentration in extracted 
heat-stabilized mouse spinal cord. Heat stabilization will be used in future studies to 
evaluate elevation of agmatine following AAV-hADC delivery to a wide spectrum of 
CNS tissues (dorsal root ganglia, selected brain nuclei, choroid plexus) in mouse and in 
rat, and under varying conditions of neural plasticity (neuropathic pain, spinal cord 
injury). From these results, we believe that this approach may become broadly applied to 
study the agmatinergic system.  
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CHAPTER 4. Gene Transfer to Choroid Plexus Cultures 
  
 
 
CHAPTER SYNOPSIS 
 
 The innate ability of the choroid plexuses to produce and secrete bioactive 
proteins into the cerebral spinal fluid (CSF) (Gonzalez et al., 2010) makes this tissue a 
potential target for central nervous system gene therapy. We have previously shown that 
intrathecal delivery of adeno-associated viral vectors results in gene transfer to the 
choroid plexus (Schuster et al., 2014ab, Chapter 2 of this thesis). In order to further 
characterize gene transfer to the choroid plexus we have developed an in vitro method for 
evaluating gene transfer to dissociated primary choroid cells, intact choroid tissue 
(explants) and immortalized choroid plexus cell line, Z310 (Zheng and Zhao, 2002).  
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INTRODUCTION 
 
 The choroid plexus is small organ inside the ventricles of the brain. The function 
of this tissue is to secrete cerebrospinal fluid (CSF), which supplies the primary fluidic 
distribution system of the central nervous system (CNS).  During the time that our 
research team has investigated the neuroanatomical distribution of gene expression of the 
adeno-associated viral (AAV) vectors we have noticed that certain AAV serotypes will 
transduce choroid plexus in vivo, while others do not. This was demonstrated 
immunohistochemically with visualized green fluorescent protein in vivo (Schuster 
2014ab). In agreement with that observation, the results that I presented in Chapter 2 of 
this thesis show that intrathecal delivery of AAV5-hADC also results in expression of 
mRNA of human ADC in freshly extracted choroid tissue.  Therefore, the possibility that 
the therapeutic effects observed from AAV5-hADC intrathecal delivery may arise from 
gene transfer to the choroid plexus, subsequent, agmatine production, and distribution 
through the CSF to target regions in the CNS.  The choroid plexus may therefore present 
an attractive target tissue for therapeutic development as a constitutive delivery source of 
endogenous therapeutics. It is not yet known, but it may be, that gene transfer to the 
choroid plexus is sufficient (e.g. in the absence of gene transfer to neurons or glia) for 
therapeutic benefit.  Such an approach could prove useful for a wide variety of gene 
therapies intended to treat a broad spectrum of CNS disorders (Johanson et al., 2005; 
Hester et al., 2009; Gonzalez et al., 2010; Gonzalez et al., 2011).   
 Although we have several reports of green fluorescent protein expression in 
choroid plexus cells following AAV delivery (Schuster et al., 2014a; Schuster et al., 
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2014b), our understanding of the suscpetibility of choroid plexus cells to gene transfer is 
fairly limited.  In order to assess the utility of specifically targeting the choroid plexus for 
gene transfer, it is important to understand its relative amenability to gene transfer 
particularly by the primary AAV subtypes used to target the CNS. The objective of the 
research featured in Chapter 4 was to quantify gene transfer to cells of the choroid plexus 
compared between three AAV subtypes commonly used to target the CNS: AAV5, 
AAV8, and AAV9 (Hester et al., 2009; Van Vliet et al., 2009; Mason et al., 2010; Dirren 
et al., 2014; Schuster et al., 2014a).  
 
The Choroid Plexus 
 The choroid does not line the ventricle, instead it sprouts from the ventricle 
ependymal cell layer in the form of a cluster of epithelial cells (Johanson et al., 2005). 
The cluster is a composed of a single sheath or monolayer of epithelium cells with 
extensive foldings. Praetorius describes the morphology of this sheath as containing a 
“basal labyrinth” or having “basal infoldings” (2007). Chodobski concurs with this 
description and describes it as a “tightly packed villous folds consisting of a single layer 
of cuboidal epithelial cells overlying a central core of highly vascularized stroma” 
(Chodobski and Szmydynger-Chodobska, 2001). The layer of epithelial cells that form 
the choroid plexus cell layer also has tight junctions (Szmydynger-Chodobska et al., 
2007; Johanson et al., 2011). The smooth, basal surface faces the microvasculature that 
supplies the choroid with blood. The luminar or ventricular surface facing the cerebral 
spinal fluid  (CSF) has lush microvilli (Matsushima, 1983; Villalobos et al., 1997; 
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Emerich et al., 2005). The choroid and cellular attributes, including transport systems, 
have been compared to that of the leaky epithelia of the kidney (Emerich et al., 2005; 
Johanson et al., 2011; Redzic, 2011).  
 
CSF Production 
 The primary function of the choroid plexus is to generate cerebral spinal fluid. As 
recently as 2007, it was believed that the choroid plexus epithelium created up to 70% of 
the cerebral spinal fluid production (Welch et al., 1966; Praetorius, 2007). However it is 
now thought to produce approximately 80% of the CSF, leaving the other 20% 
originating from interstitial fluid created by the blood brain barrier (BBB) (Damkier et 
al., 2013). CSF is generated at the rate of approximately 400 mL per day for a human 
(Johanson et al., 2005). The actual volume of CSF at any given moment in a human is 
approximately 140 ml (Pardridge, 2011). For comparison, the volume of CSF in dog is 
7.8-24 mL (Artru, 1984), 1.4 – 2.3 mL in rabbit (McComb et al., 1982), 280-300 uL in rat 
and 40 uL in mouse (Artru, 1994). It is important to note that CSF is not simply plasma 
ultrafiltrate  (Praetorius, 2007). Ninety-nine percent of the CSF is comprised of water 
with the other 1% containing ions (Na+, K+, Mg+, Cl-, HCO3-) and small proteins such 
as albumin, IgG, and trasferrin (Artru, 1999). The primary function of CSF is to provide 
buoyancy to support the weight of the brain itself, and also acts to provide protection 
against mechanical shock.  
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CSF Secretion from Choroid Plexus  
 Much literature exists on pressure-volume relationships of CSF in regards to 
hydrocephalus disorders and corresponding animal models (McMullen et al., 2012), yet 
the secretory processes and the transport systems involved in the secretion of CSF 
reamains under debate (Damkier et al., 2013).  There is a growing consensus, however, 
that CSF secretion process is primarily due to an “isotonic” transport (Damkier et al., 
2013) that utilizes a combination of aquaporins (AQP-1) (Oshio et al., 2003; Oshio et al., 
2005) and ATP-ase ion channels such as sodium, chloride,  potassium, and bicarbonate 
(Praetorius, 2007; Damkier et al., 2013) that create transcellular movement across the 
epithelium cells and into the ventricles.   
 
CSF Circulation 
 The second purpose of CSF is to provide a means for the brain to eliminate waste 
products and also to provide a way for nutrients, hormones and immune cells to circulate 
in the CNS or to be delivered/removed from the CNS (Emerich et al., 2005; Praetorius, 
2007). All of the aforementioned processes is governed by the CSF flow or circulation. 
The net movement or circulation of CSF along the spinal cord is driven by pulsations 
from cardiovascular heart and blood vessels.  As CSF is secreted by the lateral ventricles 
it is drained into the third ventricle, continues via the cerebral aqueduct into the fourth 
ventricle, and then into the subarachnoid space of the spinal cord. During the contraction 
phase of the heart cycle (systole) pressure in the arteries of the brain increases. The 
increase in blood pressure drives CSF out of the brain through the upper cervical spine 
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because as blood volume rises CSF volume must decrease. During the relaxation phase 
(diastole) the pressure drops and CSF enters the cranial vault through the subarachnoid 
space of the upper cervical spine.  
 Respiratory pressure changes supply a steady rhythm of pressure such that, as the 
chest cavity drops during inhalation, due to the diaphragm moving down and the chest 
wall moving out, CSF is pulled out of the cranial vault. As pressure in the chest cavity 
increases during exhalation CSF is driven into the cranial cavity. Thus, combined 
cardiorespiratory waves are most important to the circulation of CSF through the brain 
and cord (Praetorius, 2007; Damkier et al., 2013).  
  
The Choroid Plexus As a Target for Gene Transfer 
 The choroid plexus secretes bioactive peptides and has been considered as a 
potential target tissue for gene targeting (Gonzalez et al., 2010; Gonzalez et al., 2011).  
Targeting the central nervous system through traditional drug delivery methods (i.e. oral, 
intra-muscular, intravenous, etc.) has been limited due to challenges in circumventing 
blood-brain barrier (BBB). Accessing the cerebral spinal fluid via direct intrathecal (i.t.) 
or intracerebral ventricular (i.c.v.) injection (both of which bypass the BBB) can provide 
access to the CNS and to the choroid plexuses.  
 Intrathecal delivery of compounds via direct lumbar puncture (Hylden and 
Wilcox, 1980) enables small molecules or larger macromoleculesto distribute to the 
spinal cord parenchyma, and to the dorsal root ganglia sensory neurons.  There is also 
rostral distribution to higher brain regions by both small molecules (Hylden and Wilcox, 
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1980) and AAV viral vectors (Schuster et al., 2014a; Schuster et al., 2014b). The 
combination of intrathecal delivery and AAV-mediated gene transfer utilizes the CSF in 
the subarachnoid space to reach the apical side (CSF side) of the choroid plexus. This 
makes the choroid plexus an accessible target for the AAV-mediated gene transfer 
following intrathecal deliver.   
 We have previously reported that in vivo intrathecal delivery (direct lumbar 
puncture) of AAV5 carrying the gene for green fluorescent protein (GFP) results in 
transduction of the choroid plexus in the 4th ventricle and to a lesser degree in the 3rd 
and lateral ventricles of mice (Schuster et al., 2014a; Schuster et al., 2014b).  These 
studies were conducted in the presence of an i.v. mannitol (25%) pre-treatment, which is 
known to enhance penetration of the spinal cord and brain parenchyma. We have since 
demonstrated that in the absence of mannitol, intrathecal injection of AAV5-GFP 
transduces the choroid plexus without appreciable concomitant penetration of the brain 
parenchyma, AAV8-GFP does not transduce brain parenchyma and AAV9-GFP 
transduces a significant amount of the choroid plexus epithelium and also surrounding 
brain parenchyma (Schuster et al., 2014b). In order to further consider the utility of 
targeting the choroid plexus using viral gene vectors, we evaluated the ability of AAV5, 
AAV8 and AAV9 to transduce choroid plexus explants in vitro carrying the gene for 
green fluorescent protein (GFP).  
As stated earlier, the objective of the present study was to evaluate gene transfer   
to the epithelial cells of the choroid plexus. To accomplish this objective we used several 
strategies.  To directly compare gene transfer in vitro to the in vivo anatomy studies, we 
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elected to use green fluorescent protein (GFP) as the marker for gene transfer.   We also 
chose to compare AAV5, AAV8, and AAV9 AAV serotypes as delivery vectors since 
they are commonly and increasingly used to target the CNS (Daya and Berns, 2008; 
Zincarelli et al., 2008; Beutler and Reinhardt, 2009; Hester et al., 2009; Van Vliet et al., 
2009; Mason et al., 2010; Schuster et al., 2013; Dirren et al., 2014).  
In order to facilitate future in vitro mechanistic and physiological studies of gene 
transfer to the choroid plexus we pursued establishment of choroid plexus in vitro 
systems in three ways. First, we attempted to establish primary rat choroid plexus cell 
cultures from dissociated epithelial cells harvested from freshly dissected rodent choroid 
plexus (Villalobos et al., 1997; Zheng et al., 1998). Second, we pursued establishment of 
organotypic in vitro choroid plexus explants according the method of Gonzalez et al. 
(2010). Finally, we acquired an immortalized choroid plexus cell line, developed by a 
Purdue University faculty member (Zheng and Zhao, 2002) and widely used in studies of 
blood-choroid plexus barrier transport (Szmydynger-Chodobska et al., 2007; Kläs et al., 
2010).  Through these studies I established both proof-of-concept that the choroid plexus 
epithelial cells are transducible by all three serotypes and the relative time course for 
gene transfer in vitro by each of these serotypes. 
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MATERIALS AND METHODS 
Primary Choroid Cultures: Dissociated Cells 
 Male ICR-CD1 mice (Harlan, WI), 21-24 grams were used for dissociated in vitro 
experiment. Subjects were housed in groups of four in a temperature- and humidity-
controlled environment and maintained on a 12-hour light/dark cycle with free access to 
food and water. These experiments were approved by the University of Minnesota’s 
Institutional Animal Care and Use Committee.  
 All cell culturing solutions and reagents are from Gibco® by Life Technologies 
(Grand Island, NY), unless otherwise noted.  Fourth ventricle choroid plexus tissue was 
extracted from twenty mice and dissociated to cells according to the method of Zheng 
and colleagues (1998). Cells were counted with a hemacytometer using the trypan blue 
(0.4%) (Sigma) exclusion method for cell viability. Twenty choroid plexuses derived 
from the 4th ventricle yielded approximately 100,000 cells per mL.  Cells were seeded 
50,000 cells per well in 24-well plate with glass coverslips pre-coated with laminin. The 
media contained the following: 50% DMEM, 50% F-12 Media with 5% FBS (Hyclone), 
1% 5fU, 1% antibiotic-antimycotic, and 0.01% EGF (10 ng/ml). Half of the wells were 
treated the same day with 5 x 1010 vg per well of AAV5-GFP and returned to the 
incubator at 95% O2 and 5% CO2. The day of fixing, the coverslips were treated with a 
solution of 4% paraformaldehyde and 0.2% picric acid in 0.1M phosphate buffer, pH 6.9. 
The coverslips were rinsed and then incubated at room temperature for 1 hour in diluent 
(PBS containing 0.3% Triton, 1% BSA, and 1% normal donkey serum) and incubated 
overnight at 4°C in primary antisera diluted in the same solution. Primary antibodies 
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used; Rb anti-GFP 1:1000 (Invitrogen), Rb anti-TTR 1:1000 (Dako, Carpinteria, CA). 
After rinsing with PBS, sections were incubated for 1 h at room temperature with 
appropriate combinations of Cy2- and Cy3-, (1:300) conjugated secondary antisera 
(Jackson ImmunoResearch, West Grove, CA).  
  
Primary Choroid Explants 
 Subjects were Sprague-Dawley male rats (Harlan, Madison, WI) with an average 
weight 200g. Subjects were housed in groups of four in a temperature- and humidity-
controlled environment and maintained on a 12 hr light/dark cycle with free access to 
food and water. Subjects were anesthetized by isoflurane-overdose and the brain was 
carefully removed intact. Fourth ventricle choroid plexus was removed by lifting the 
cerebellum. Third and lateral ventricles were exposed by making a parallel incision 
approximately 5 mm from the midline. Forceps were used to extract the choroid tissues 
and placed in media described above. The procedures for culturing, incubation, fixation 
and immunohistochemistry were the same as described in section above. 
 
Immortalized Choroid Plexus Cell Line (Z310 Cells) 
 All cell culturing solutions and reagents are from Gibco® by Life Technologies 
(Grand Island, NY), unless otherwise noted. The Z310 cell line, a cell line reported to be 
representative of the choroid plexus (Zheng and Zhao, 2002), was a generous gift of Prof. 
Wei Zheng of Purdue University and was obtained on the Material Transfer Agreement 
on file with Office of Sponsored Projects Administration at Purdue University and the 
  104 
University of Minnesota. The cells arrived on dry ice and were immediately transferred to 
flask culture as per enclosed Zheng Lab standard operating procedure. An 85-90% 
confluent flask yielded on average 7 - 8 x 106 viable cells per mL via hemocytometer and 
trypan blue assay (0.4%, Sigma Aldrich). In vitro cell cultures of the immortalized 
choroid epithelium Z310, were plated at a ratio of 1:64 in a media consisting of 10% 
FBS, 1% pen/strep, 0.2% gentamicin, 0.01 hEGF in sterile high glucose DMEM. The 
growth of the Z310 cells is very robust and reached confluency in 24-36 hours post 
seeding. Therefore a slight modification was made by using low glucose DMEM to 
slightly inhibit the growth of the cells.  
 For immunohistochemical staining, fixation was performed by using a 4% 
paraformaldehyde solution. These fixed coverslips were rinsed by gentle dipping into 
room temperature PBS. Primary antibodies used were chicken anti-GFP (1:2000) 
(Abcam™) with a secondary of Cy-2 donkey anti-chicken (1:300) (Jackson 
ImmunoResearch, West Grove, CA). The coverslips were again rinsed by gentle dipping 
in room temperature PBS and were mounted to slides with Vectashield with DAPI 
mounting medium (Vector Laboratories, Burlingame, CA). 
 
Well Plate and Cover Slip Preparation  
 Prior to seeding, 22 mm x 22 mm coverslips, No. 1 thickness (Erie Scientific 
Company, Portsmouth, NH) were washed in 0.1M HCl at a temperature of 50-60°C for 1 
hour. Triple rinsed with DI water and triple rinsed with 95% ethanol and stored in 95% 
Ethanol. The day of seeding, one coverslip per well of a sterile 6-well plate (Corning 
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3516, Corning, NY) was placed in each well and allowed to evaporate in culturing hood. 
A sterile solution of laminin (dissociated and explants cultures) or poly-D-Lysine (Z310 
cultures) was applied to the coverslip within the well as per manufacturer protocol, and 
allowed to dry in the cell culture hood until dry.  
 
Viral Vector  
 The viral vectors for adeno associated viral (AAV) vector serotype 5, 8, 9 (AAV5, 
AAV8, AAV9) were purchased from the University of Florida Vector Core (Gainesville, 
Florida). These vectors all contained the CMV promoter which is the same promoter used 
in the AAV-hADC-GFP construct. In all studies, each well was treated with 2.5 µL 
vector stock/well of the following: AAV5 (stock concentration 7.17x1012 vg/ml), AAV8 
(stock concentration 4.0 x 1012 vg/ml), or AAV9 (stock concentration 3.3 x1011 vg/ml) or 
saline.  
 
Immunopositive GFP Cell Counting (Blinded) 
 The degree and time course of transduction was assessed with 
immunohistological staining methods using antibodies against and GFP (Abcam ™). The 
numbers of positive GFP cells were quantified by two separate observers who were 
blinded to the treatment and time points. Briefly, the slide was placed on the microscope 
and viewed under the UV channel at 40X magnification. An area was randomly selected 
and the DAPI labeled nuclei were brought into focus. Once in focus, the channel was 
switched to Cy-2 to observe GFP positive cells. If present, the number of GFP positive 
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cells and the relative area was noted. The observer then moved to another location and 
repeated the process for up to 10 locations on the 22 mm x 22 mm coverslip and recorded 
their counts in the laboratory notebook. No significant difference was found between the 
values obtained by the two blinded experimenters (Student’s t-test, p<0.05).  
 
RT-PCR   
 Total RNA was extracted from Z310 cells treated with AAV9-hADC-GFP, and 
RT-PCR was performed using the techniques described in Chapter 2. 
 
 
RESULTS 
Primary Choroid Cultures: Dissociated Cells 
 In the dissociated mouse choroid experiments it was confirmed that the cells 
exhibited presence of transthyretin (TTR). Transthyretin is secreted by the choroid plexus 
into the cerebrospinal fluid and is used as a marker of choroid plexus epithelial cells 
(Monnot and Zheng, 2013).    
 Green fluorescent protein (GFP) was detected immunohistochemically in 
dissociated choroid plexus epithelial cells after 48 hours in culture and co-localized in 
cells expressing transthyretin (Figure 4.1C and 4.1D). Such co-localization confirms 
AAV5-GFP gene transfer to choroid plexus epithelial cells. However, the number of cells 
transduced was quite limited. We reasoned that a longer incubation time might be 
needed. However, it was noted that there was pronounced lifting of the cells from the 
laminin pre-treated cover-slips at 2 days in culture and therefore, our assessment was that 
the acute dissociated culture approach would have limited utility for time-expression 
studies of gene transfer to choroid plexus epithelial cells.  
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Primary Choroid Explants  
 It was next attempted to optimize a system using explants of intact choroid plexus 
from the fourth ventricle.  The rationale was that maintaining the structural architecture 
(microvasculature included) of the choroid plexus tissue may better mimic the in vivo 
condition. With dissociated cells, the combination of 20 fourth-ventricle choroid plexuses 
yielded only enough cells to seed 4 wells, enough for 2 treated wells and 2 control wells. 
It was suggested that plating each choroid separately, but intact, would result in improved 
sample survival. This approach enabled additional vectors to be tested as well as reduce 
the need for media changes.  
The experiments treating intact choroid plexuses of rat allowed for a total of 24 
choroid explants to be plated which enabled a viral particle concentration-response study 
for both AAV5-GFP and AAV8-GFP to be conducted. The explants were either treated 
with 1 µL of PBS (n=6), 1X (109 vp/well), 0.1X (108 vp/well) or 0.01X (107 vp/well) 
dilutions of the AAV5-GFP or AAV8-GFP (n = 3 per treatment group per vector). 
Compared to the dissociated culture approach, the explant technique facilitated a longer 
post-viral vector incubation time; the choroid plexuses were fixed after 72 hours post-
AAV-GFP treatment. Upon viewing with fluorescence microcopy, it was determined that 
the explants receiving the 1X treatment (109 vp/well) of AAV5-GFP or AAV-8-GFP 
resulted in the strongest GFP visualization (Figure 4.2, lower concentrations not shown).  
Control explants did not result in GFP staining (Figure 4.2A). In the treatment 
explants, the AAV5-GFP-treated choroid plexus showed greater immunopositivity for 
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GFP, although those treated with AAV8-GFP were also positive for GFP relative to 
control. Three of the controls were not fixed but stained with trypan blue and assessed for 
viability. The cells on the outside surface took up trypan blue indicating that the cells 
were dead. However, the center of the explants excluded trypan blue, even after 30 
minutes of incubation. It was noticed that the vascularization of the choroid explants was 
visible under 20X magnification 72 hours after extracting. This vasculature was not 
visible at 20X magnification immediately after extraction. It was noted that microscopy 
on the 3-dimensional explant proved difficult to achieve one plane of focus and images 
were taken on the periphery of the tissue under the coverslip. Overall, the GFP expression 
observed in the choroid plexus explants concurred with the dissociated cells in that the 
choroid plexus epithelial cells are amenable to gene transfer. However, here again, the 
limitations of survival of the total explant and difficulty of imaging with 3-D nature of 
sample, suggested that the system might be of limited utility for the studies planned.  
 
Immortalized Choroid Plexus Cell Line (Z310 Cells) 
 In the course of developing and researching other choroid cell culturing 
techniques it came to our attention that the Z310 immortalized mouse choroid plexus 
epithelial cell line might be beneficial to the proposed studies. By using low glucose 
media instead of high glucose DMEM the immortalized cells allowed for incubation 
times up to 96 hours without the need to change media, enabling a significantly greater 
duration of exposure to the viral particles. The wells were treated with 2.5 µL of either 
saline AAV5-GFP, AAV8-GFP or AAV9-GFP. The increased treatment volume was to 
adjust for the use of larger 6-well plates instead of 24-well plates. After 24 hours, cells 
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immunopositive for GFP were present (Figure 4.3) in all AAV-treated cells. This pattern 
continued and increased for each vector and each subsequent time point (Figure 4.3).  
 After fixation and immunohistological labeling, it was noted at 48 hours that the 
cell layer was confluent on the coverslip. By 72 hours the cell layer was proliferating 
vertically and appeared 2-3 layers thick in multiple areas on the coverslip. By 96 hours 
the cell layer was 4-5 layers thick. Therefore, the images were taken in slices and 
compiled to produce a planar image.  
 There was a significant difference in GFP expression between 24 and 96 hours in 
AAV5-, AAV8-, and AAV9-GFP-treated groups as determined by one-way ANOVA; 
this observation documented an overall effect of time on GFP expression (Figure 4.4). 
Tukey’s post-hoc test for multiple comparisons between groups confirmed significant 
difference between most time points. In summary, the results of this time course study 
indicate that AAV5, 8, and 9, were all capable of transducing the immortalized choroid 
plexus epithelial cells in a time-dependent manner.  The robustness of the system led us 
to conclude that the Z310 cell line offers the greatest utility for studies of gene transfer to 
the choroid plexus.  
 
 Gene Transfer of AAV5-hADC to Immortalized Choroid Plexus Cells 
 Following optimization of the culturing parameters for the Z310 cells a small 
study was performed in which Z310 cells were exposed to AAV5-hADC-GFP. The cells 
were treated with with 2.5 µL of PBS or AAV9-hADC-GFP.  After 72 hours, the cells 
were collected and a portion of them were analyzed for hADC mRNA content. The result 
indicated that the Z310 cells do not have native hADC present but the cells treated with 
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AAV5-hADC-GFP were positive for hADC mRNA content. These results confirmed that 
the Z310 cells are amenable to AAV5-mediated gene transfer and can express mRNA 
from a second gene; this cell line may prove optimal for further studies of hADC 
expression and possible release of agmatine from the choroid plexus.  
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Figure 4.1: AAV in vitro delivery to dissociated primary mouse choroid culture 48 hours 
post treatment. A) Red = Transthyretin (TTR) (choroid cell marker)  B) Green= GFP; 
Yellow indicates co-localization at C) 40X and D) 10X magnification.   
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Figure 4.2: AAV5-GFP and AAV8-GFP ex vivo delivery to intact rat choroid plexus 
explants at 60X. A) Untreated control B) AAV5-GFP treated ex vivo. C) AAV8-GFP 
treated ex vivo.  (Green = GFP, Blue = DAPI) 
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Figure 4.3: AAV5-GFP, AAV8-GFP, and AAV9-GFP delivery to immortalized choroid 
plexus cell line, Z310, 24, 28, 72 and 96 hours post treatment. (Green = GFP, Blue = 
DAPI, White = Colocalization)  
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Figure 4.4: Bar graph representation of positive GFP cells in Z310 cells over time: 24-, 
48-, 72-, and 96-hours post treatment with either AAV5-GFP, AAV8-GFP, AAV9-GFP 
or saline. * Indicates a significant difference between 24 hours and 96 hours within each 
treatment group, AAV5-GFP (p<0.0001), AAV8-GFP (p<0.0005), and AAV9-GFP 
(p<0.0001) One-way ANOVA with Tukey’s post hoc test for multiple comparisons 
between groups. 
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DISCUSSION 
 
Despite decades of sophisticated targeting of a wide variety of molecular systems 
identified as important for chronic pain, management of chronic pain remains an area in 
grave need of new approaches. Gene transfer utilizing the non-pathogenic adeno-
associated virus shows great promise in the specific targeting of CNS tissues, especially 
those related to chronic pain (Beutler and Reinhardt, 2009; Vulchanova et al., 2010).  By 
utilizing the cerebral spinal fluid (CSF) in the subarachnoid space, the viral vector 
particles can be distributed to the brain thereby transferring long-term genetic 
modifications to the choroid epithelium.  Specifically, AAV is a non-pathogenic virus 
with multiple serotypes that have unique tropisms to a variety of tissues. In order to 
further characterize AAV gene transfer to the choroid plexus we have applied an in vitro 
and ex vivo method for culturing primary and intact choroid tissue collected from both 
mouse and rat respectively.  We show here that both AAV5 and AAV8 as well as AAV9 
target the choroid plexus in vitro and ex vivo. 
 
 
SUMMARY AND CONCLUSIONS 
 
Although the choroid plexus is not a tissue commonly associated with sensory 
processing, we have shown previously in in vivo studies that intrathecal delivery of 
specific AAV vectors will transduce choroid plexus epithelial cells (Schuster et al., 
2014a; Schuster et al., 2014b). Based on this previous in vivo experimentation, we 
originally predicted that AAV5 and AAV9 would yield greater transduction and tropism 
to choroid plexus epithelium relative to AAV8. Through the present study in three 
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distinct in vitro preparations we have confirmed the amenability of choroid plexus 
epithelial cells to AAV-mediated gene transfer, by all three AAV serotypes. These initial 
studies have provided information on optimal in vitro choroid plexus cell culture 
conditions for future studies of in vitro gene transfer. 
The results presented here in Chapter 4 illustrate the utility of the in vitro 
immortalized choroid plexus cell line method for further evaluation of gene expression 
and function in choroid plexus epithelial cells. Gene transfer to the choroid plexus 
following intrathecally delivering adeno-associated viral gene therapy may represent 
potentially advantageous strategy for the delivery of gene therapy for neurological 
disorders, especially that of chronic pain. 
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Chapter V. Summary, Future Directions, and Conclusion. 
 
SUMMARY 
 The research approach and observations featured in this thesis have shown the 
feasibility of gene transfer in vivo (Chapter 2) and in vitro (Chapter 4) to central nervous 
system related-tissues or choroid plexus cells, with AAV viral vectors. The quantification 
results in Chapter 3 suggest that the observed increase in spinal concentrations of 
agmatine is due to the expression of hADC enzyme in transduced regions of the CNS. 
The observation of elevated spinal agmatine presented in Chapter 3 corroborates the 
findings of Chapter 2 where subjects treated with AAV-hADC fail to develop opioid 
analgesic tolerance. Together those observations parallel that of previous observations 
showing that spinally delivered exogenous agmatine prevents the development of both 
morphine (Fairbanks et al., 1997) and endomorphin-2 analgesic tolerance (Wade et al., 
2009). Given the significant challenge in chronic use of opioids for the clinical 
management of chronic pain, the observation that expression of human ADC prevents the 
development of opioid analgesic tolerance suggests that this strategy could be clinically 
advantageous as a gene therapy. However, the source of the elevated agmatine and 
potential long-term effects are not yet fully understood.   
  121 
FUTURE DIRECTIONS 
The data presented in this thesis demonstrate that gene transfer to the choroid 
plexus in vivo results in elevated expression of hADC. Expression of hADC in choroid 
plexus may result in the ability of freely available L-arginine to be converted into 
agmatine. It is possible that the elevated agmatine is then secreted from the epithelial 
choroid plexus cells and circulated through the CSF. The human choroid plexus epithelial 
cells exhibit near identical distribution of transporters to the of rat and mouse choroid 
plexus (Damkier et al., 2013). Therefore, there should be good correspondence between 
the pre-clinical models and the human condition. However, there was some notable 
differential transduction of choroid plexus between in vivo and in vitro systems. We 
suspect this is due to differences in the cell surface receptors of the choroid plexus 
epithelial cells or diffusional differences in the in vivo environment.  This may limit the 
applicability of the in vitro system with respect to some viral vector serotypes.  
 As for the utility of the Z310 immortalized cell line, it has been proposed that the 
Z310 cell lines are similar to in vivo choroid plexus in regards to transthreytin production 
and polarity (Zheng 2002, Kitazawa et al., 2001; Ramanathan, 1996; Zheng, 1998), as 
well as the functional transporters P-gp and Mrp1 (Kläs and Reichel, 2010). However, a 
recent study has raised issue when using this cell line as a true representative of the 
blood-cerebrospinal fluid barrier (BCSFB) due to lack of presence of certain tight 
junction proteins (Kläs and Reichel, 2010). For our studies of gene expression the latter 
limitation may not be of significant concern. The in vitro choroid plexus epithelial cells 
system that we characterized in Chapter 4 would enable studies to further characterize the 
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outcomes of AAV gene transfer to choroid plexus and subsequent release of therapeutics 
into the CSF.    
  The potential therapeutic utility of selective gene targeting to the choroid plexus 
has been recognized by others (Gonzalez et al., 2010; Gonzalez et al., 2011; Haddad et 
al., 2013); however, to our knowledge, methods to exclusively transduce the epithelial 
cells of the choroid plexus remain limited at the present time. Rejev and colleagues 
(2010) reported that the choroid-specific promoter corticotropin releasing factor receptor 
type 2 beta (CRFR2β) provides exquisite specificity for the choroid plexus. Lentiviral 
vectors containing this promoter and the gene for GFP demonstrated expression of GFP 
only in choroid epithelial cells following intracerebroventricular (i.c.v.) delivery. In 
another study, it was found that the baculovirus specifically target the choroid plexus 
when delivered i.c.v. (Lehtolainen et al., 2002). 
 A second strategy is currently being developed by Kaler and colleagues at the 
National Institutes of Health. This research group is reportedly undertaking the selective 
development of a recombinant AAV vector with specific viral capsid motifs that will 
specifically target choroid plexus cells (Kaler, NIH). Application of either of these 
choroid-specific molecular tools would importantly enable true assessment of the utility 
of choroid plexus-specific gene targeting for a broad spectrum of CNS disorders.  
The impact on the intrinsic functions of the choroid itself in vivo (such as changes 
in CSF production) when AAV gene therapy is administered would also need to be 
assessed. It would be essential that CSF production proceeds unchanged (McMullen et 
al., 2012). Some initial studies have evaluated CSF pressures and ventricle size following 
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viral vector delivery (McMullen et al., 2012). These types of long range toxicity studies 
would need to be conducted extensively to assess safety of AAV-mediated gene transfer 
to the choroid plexus (Beutler and Reinhardt, 2009; Kumar et al., 2011). 
 Even though it is known that AAV vectors can be modified in such a way as to 
provide therapeutic or beneficial treatments in pre-clinical models, the translation of such 
therapy to humans has been proceeding with “cautious optimism” (Asokan et al., 2012). 
This cautiousness is due to unpredicted, adverse, immunological reactions to viral-
mediated gene therapies. During the advent of gene therapy there was much excitement 
over the possibilities and future of gene therapy. The successful treatment of a young 
child that was cured of her X-linked Severe Combined Immune Deficiency (Blaese et al., 
1995) provided motivation for researchers to explore other therapies. However, with 
time, other children receiving a similar therapy developed leukemia due to the 
mutagenesis of the virus integration near a proto-oncogene (Hargreaves, 2002) and the 
trials have since been stopped. There have also been tragic fatalities that have been 
widely covered by the media. One well known case is the treatment of Jesse Gelsinger, 
an eighteen year old who died after receiving gene therapy to correct his ornithine 
transcarbamylase deficiency (Raper et al., 2003). These cases brought to light many 
considerations when using gene transfer as a therapy, such as the fact that there is no off 
switch in gene-transfer therapy and that the immunological responses of every individual 
cannot always be accurately predicted (Kimmelman, 2009).  Thus far, pre-clinical data 
has reported little to no adverse side effects with centrally delivered AAV-mediated 
therapies (Beutler et al., 2005; Hadaczek et al., 2010; Samaranch et al., 2012; San 
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Sebastian et al., 2013); however there is no guarantee the same will hold true in humans. 
Therefore the FDA has worked with researchers and clinicians to create a guidance for 
gene therapy clinical trials (FDA, 2006) that call for extensive toxicological studies and 
long-term immunological monitoring of subjects immune status many years following 
gene delivery (FDA, 2006; Kimmelman, 2009). However, these guidances are often 
written for studies utilizing viral vectors with a high chance of reactivation or delayed 
adverse events, such as gammaretrovirus, lentivirus, and herpes virus (FDA, 2006). How 
AAV-mediated gene transfer fit into these guidances, is not specifically addressed.  
 In his book chapter, describing the risks of gene transfer in clinical research, 
Kimmelman emphasizes that there is a specific need for uniform regulations and 
systematic testing of AAV-mediated therapies (2009). There is also a need for 
standardization, not only for study design, but for a system that collects safety and 
toxicological data in an organized and easily accessible fashion (Kimmelman, 2009). As 
this relates to the work in this thesis, more research is necessary to assess the long-term 
safety of i.t. delivery of AAV-hADC in mice and eventually larger animal models and 
potentially non-human primates. Others have taken this approach and are finding in 
Phase I trials that AAV delivery is tolerable when administered directly into the CNS 
(Beutler et al., 2005; Hadaczek et al., 2010; Samaranch et al., 2012; San Sebastian et al., 
2013).  
 There is a general consensus that AAV is nonpathogenic and is naturally 
replication defective. There was a reported case of hepatotoxicity due to the AAV2 
serotype vector in a therapy for hemophilia (Manno et al., 2006). Since most adults are 
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seropositive for AAV antibodies, delivery of AAV-gene transfer is often unsuccessful 
with intravenous or intramuscular administration (Chirmule et al., 1999). The AAV 
capsid is the primary interface between the host and vector genome and it is believed that 
the capsid moderates specificity of transduction and immune response. Second generation 
AAV vectors have been re-engineered to lessen the immune response to the AAV capsid 
(for a full review see Asokan, et al., (2012). AAV vectors have a variety of serotypes to 
enable cell targeted entry (Gao et al., 2005), and display unique tissue tropisms. Thus, 
AAV-mediated gene transfer has become a hopeful strategy in the translation of animal-
based research to human clinical trials (Beutler and Reinhardt, 2009; Asokan et al., 
2012).  
 
CONCLUSION 
 As stated in the Introduction to this thesis, the National Institute of Medicine 
estimates that over 116 million Americans have common chronic pain conditions 
(Institute of Medicine Committee on Advancing Pain Research, 2011). Yet, the most 
current and popular treatments often fail to achieve all the therapeutic goals for 
eliminating or significantly reducing the patient’s discomfort. Often times the patient’s 
treatment will be temporary and can lead to invasive procedures or escalated doses of 
pharmaceutics associated with unacceptable side effects (Finegold et al., 1999). The 
financial ramifications of chronic pain are severe with costs estimating $635 billion or 
more each year in medical treatments and lost productivity (Institute of Medicine 
Committee on Advancing Pain Research, 2011). Therefore, new approaches and 
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solutions to chronic pain are necessary such as the gene therapies described in this thesis. 
It is hoped that the information gathered as a result of this doctoral thesis research project 
will assist in the goal of discovering new approaches to treating and ameliorating chronic 
pain. 
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